CN110582206A - Purposefully selected compositions comprising purified cannabinoids and/or purified terpenes - Google Patents

Abstract

disclosed herein is a novel composition comprising a purified cannabinoid and a purified terpene. In one embodiment, the composition comprises one or more purified cannabinoids. In one embodiment, the composition comprises a combination of one or more purified cannabinoids and one or more purified terpenes. In one embodiment, the composition comprises a non-naturally occurring proportion. In one embodiment, the composition comprises a non-naturally occurring concentration. In one embodiment, the composition comprises an unexpected and/or synergistic effect.

Description

purposefully selected compositions comprising purified cannabinoids and/or purified terpenes

Technical Field

The present disclosure relates to the hemp industry. In particular, the present disclosure relates to compositions and formulations comprising novel, purposefully designed combinations of purified compounds.

Background

The term "cannabis" refers to the flowering plant genus. Cannabis plants include a variety of species including Cannabis vulgaris (Cannabis sativa), Cannabis indica (Cannabis indica) and Cannabis ruderalis (Cannabis ruderalis). Hemp has long been used in hemp fiber, in seeds and seed oils, for medical purposes, and as a recreational drug.

According to some reports, cannabis is composed of at least 483 known compounds including cannabinoids, terpenoids, flavonoids, nitrogenous compounds, amino acids, proteins, glycoproteins, enzymes, sugars and related compounds, hydrocarbons, alcohols, aldehydes, ketones, acids, fatty acids, esters, lactones, steroids, terpenes, non-cannabinoid phenols, vitamins and pigments.

Cannabinoids are of particular interest in research and commercialisation. Most extractions of cannabis plant matter are aimed at extracting cannabinoids, in particular Tetrahydrocannabinol (THC). THC is used for pain relief, treatment of glaucoma and nausea relief. THC is also becoming increasingly popular as a recreational drug. Generally, cannabinoids are extracted from the cannabis plant as part of a crude mixture, combined with other compounds found in the cannabis plant.

despite the progress made in isolating the small amounts of cannabinoids and terpenes found in cannabis plants, no work has been done in formulating compositions with specific combinations containing these compounds in purified or isolated form. Some of the less common cannabinoids were neither isolated nor studied individually or in any combination. In addition, there has been little or no work to develop compositions with purposefully designed, reproducible, consistent and reliable ratios of purified cannabinoids. In particular, there has been no development of a combination of cannabinoids with purified terpenes.

There is a need for compositions comprising new artificial combinations of purified cannabis components. In particular, there is a need for compositions comprising a novel combination of at least one cannabinoid and at least one purified terpene.

disclosure of Invention

Disclosed herein are novel compositions comprising purified cannabinoids and/or purified terpenes. In one embodiment of the disclosure, a composition comprises a first purified cannabinoid and a first purified terpene. In one embodiment of the disclosure, a composition comprises a first purified cannabinoid and a second purified cannabinoid. In one embodiment of the disclosure, a composition comprises a first purified cannabinoid, a second purified cannabinoid, and a first purified terpene. In one embodiment of the disclosure, a composition comprises a first purified cannabinoid, a first purified terpene, and a second purified terpene.

The compositions disclosed herein are purposefully formulated to provide artificial, non-naturally occurring combinations, concentrations, and/or ratios of compounds sometimes found in naturally occurring cannabis plants.

In one embodiment, the compositions disclosed herein include a first purified cannabinoid and a first purified terpene in a non-naturally occurring ratio. In one embodiment, the compositions disclosed herein include a non-naturally occurring concentration of a first purified cannabinoid and a first purified terpene.

In one embodiment, the compositions disclosed herein comprise a first purified cannabinoid and a second purified cannabinoid in a non-naturally occurring ratio. In one embodiment, the compositions disclosed herein comprise a first purified cannabinoid and a second purified cannabinoid in a non-naturally occurring concentration.

In one embodiment, the compositions disclosed herein comprise a first purified cannabinoid, a second purified cannabinoid, and a first purified terpene in a non-naturally occurring ratio. In one embodiment, the compositions disclosed herein include a first purified cannabinoid, a second purified cannabinoid, and a first purified terpene in a non-naturally occurring concentration.

In one embodiment, the compositions disclosed herein comprise a first purified cannabinoid, a second purified cannabinoid, and a third purified cannabinoid in a non-naturally occurring ratio. In one embodiment, the compositions disclosed herein comprise a first purified cannabinoid, a second purified cannabinoid, and a third purified cannabinoid in a non-naturally occurring concentration.

in one embodiment, the compositions disclosed herein comprise a first purified terpene, a second purified terpene, and a first purified cannabinoid in a non-naturally occurring ratio. In one embodiment, the compositions disclosed herein include a first purified terpene, a second purified terpene, and a first purified cannabinoid in a non-naturally occurring concentration.

In one embodiment of the disclosure, the composition comprises a non-naturally occurring ratio of purified cannabinoid to purified terpene of 10: 1-1: 1.

In one embodiment of the disclosure, the composition comprises a non-naturally occurring ratio of purified cannabinoid to purified terpene of 10: 1-5: 1.

In one embodiment of the disclosure, the composition comprises a non-naturally occurring ratio of purified cannabinoid to purified terpene of greater than 10: 1.

disclosed herein are compositions comprising:

A first purified cannabinoid; and

A compound selected from the group consisting of a second purified cannabinoid or a first purified terpene,

wherein the composition is substantially cellulose free.

As used in the context of this application, the term "purified" means extracted, separated and/or separated from other compounds, preparations, compositions, substances and/or blocks. In one embodiment, the term "purified" refers to cannabinoids that are separated from the plant material from which they are derived.

In one embodiment, the term "purified" refers to cannabinoids ("purified cannabinoids") that are separated from other cannabinoids present in the plant material from which they are derived. In one embodiment, the term "purified" refers to cannabinoids ("purified cannabinoids") that are separate from the terpenes present in the plant matter from which they are derived. In one embodiment, the term "purified" refers to cannabinoids ("purified cannabinoids") that are separated from secondary compounds (secondary compounds) present in the plant matter from which they are derived. In one embodiment, the term "purified" refers to cannabinoids ("purified cannabinoids") that are separated from all the material present in the plant material from which they are derived.

In one embodiment, the term "purified" refers to a terpene that is separated from other cannabinoids present in the plant material from which it is derived ("purified terpene"). In one embodiment, the term "purified" refers to terpenes that are separate from the terpenes present in the plant matter from which they are derived ("purified terpenes"). In one embodiment, the term "purified" refers to terpenes that are separated from secondary compounds present in the plant matter from which they are derived ("purified terpenes"). In one embodiment, the term "purified" refers to terpenes that are separated from all materials present in the plant material from which they are derived ("purified terpenes").

in the context of the present disclosure, a purified compound can be purposefully formulated with other compounds at various purity levels. For example, depending on the desired result, a particular cannabinoid or terpene can be formulated with other molecules when it is 60-65% pure, 65-70% pure, 70-75% pure, 75-80% pure, 80-85% pure, 85-90% pure, 90-95% pure, 95-99% pure, 99-99.9% pure, 99.9 +%, or greater than 99% pure. If ingredients for a purposeful formulation are purified prior to the purposeful formulation, the act of subsequently formulating them does not "purify" them within the scope of the ingredient list.

in one embodiment, purified means "substantially free" of other materials, such as compounds, particulates, nutrients, plant-derived materials, solvents, and the like. In one example, the term "purified" refers to a compound that is purified from a crude extract. E.g., biologically derived substances or BDS, resulting in significant differences between the purified compounds and the extract. In one embodiment, substantially free means that the compound does not contain (or in negligible amounts) other materials.

In the context of the present disclosure, the term "plant" refers to whole plants and parts of plants, such as leaves, roots, bark, flowers and the like. The term plant also includes dried plants and dried parts of plants.

within the scope of the present disclosure, wherein a compound contains a stereocenter, the term "purified" includes isolated stereoisomers and also includes mixtures of stereoisomers, provided that the compound with the stereoisomers is free of other compounds having different atom connectivity.

As used in the context of this application, the term "artificial" means designed or purposefully created by humans, as opposed to natural "nature" without human influence. In one embodiment, an artificial composition is a preparation made by combining naturally occurring molecules in a novel non-natural manner, for example, by isolating individual chemical components of a plant and then recombining some of these components to achieve different concentrations and/or ratios of these components. In one embodiment, the artificial composition is a preparation made in one or more methods in a chemical extraction and purification laboratory.

the nature of the compositions of the present disclosure-made by purposefully combining purified compounds in concentrations, combinations, and/or ratios-is different from pre-existing techniques, such as extracts or other processed materials, such as biopharmaceutical substances, medical grade plant extracts, and the like.

in one embodiment, purification includes the use of various solvents, such as ethanol, butane, methane, carbon dioxide, ice, water, steam. In one embodiment, purification includes various techniques, such as chromatography, crystallization, filtration, centrifugation, and the like, or various combinations of the described techniques. In one embodiment, purification includes extracting cannabinoids and other plant molecules from the cultivated plant to express the desired cannabinoid and/or terpene profile to obtain purity.

The term "cellulose" as used herein refers to a cellulose having the formula (C)₆H₁₀O₅)_nthe organic compound of (1). In one embodiment, the phrase "substantially cellulose free" is intended to refer to naturally occurring plants (e.g., a plant that does not contain cellulose)Such as a cannabis plant) is distinguished from isolated compounds (e.g., cellulose) that do not contain plant material.

as used herein, the term "naturally occurring" refers to occurring, or synthesized in nature. In one embodiment, naturally occurring refers to a secondary compound synthesized in plants. In one embodiment, naturally occurring refers to the collection of cannabinoids synthesized in cannabis. In one embodiment, naturally occurring refers to the concentration of a compound in a plant. In one embodiment, naturally occurring refers to the concentration of cannabinoids in cannabis. In one embodiment, naturally occurring refers to the proportion of secondary compounds in a plant. In one embodiment, naturally occurring refers to the ratio of the first cannabinoid to the second cannabinoid in a cannabis plant.

As used herein, the term "naturally occurring ratio" refers to the ratio of one or more compounds relative to another compound or compounds in the cannabis plant. In one embodiment, the naturally occurring ratio is the amount of cannabinoid relative to the amount of cannabinoid in the cannabis plant. In one embodiment, the naturally occurring ratio is the amount of cannabinoid relative to the amount of terpene in the cannabis plant. In one embodiment, the naturally occurring ratio is the amount of cannabinoid relative to the amount of terpene in the cannabis flower. In one embodiment, the naturally occurring ratio is the amount of cannabinoid relative to the amount of terpene in the genus plant extract. In one embodiment, the naturally occurring ratio is the amount of cannabinoid relative to the amount of terpene in a formulation prepared from a cannabis plant extract.

In one embodiment, the naturally occurring ratio is expressed as a molar ratio. In one embodiment, the naturally occurring ratio is expressed as mass. In one embodiment, the mass and/or molar ratio is measured by chromatography and/or spectroscopy.

As used herein, the term "non-naturally occurring ratio" refers to the ratio of one or more compounds relative to another compound or compounds in a composition produced by a human. In one embodiment, the non-naturally occurring ratio is the amount of cannabinoid relative to terpene and is not observed in cannabis plants. In one embodiment, the non-naturally occurring ratio is expressed as a molar ratio. In one embodiment, the non-naturally occurring ratio is expressed as a mass. In one embodiment, the mass and/or molar ratio is measured by chromatography and/or spectroscopy.

In one embodiment, the non-naturally occurring ratio is the amount of cannabinoid relative to the amount of terpene in a human formulated composition not observed in cannabis. In one embodiment, the non-naturally occurring ratio is the amount of cannabinoid relative to the amount of a second cannabinoid in a composition formulated by a human that is not observed in cannabis.

As used herein, the term "naturally occurring concentration" refers to the amount of one or more compounds relative to the entire naturally occurring reference sample. In one embodiment, the naturally occurring concentration is the amount of cannabinoid in the cannabis plant sample. In one embodiment, the naturally occurring concentration is the amount of cannabinoid in dried or solidified flowers of cannabis. In one embodiment, the naturally occurring concentration is the amount of cannabinoid in the crude extract of cannabis.

In one embodiment, the naturally occurring concentration is the amount of terpenes in the cannabis sample. In one embodiment, the naturally occurring concentration is the amount of terpene in dried or solidified flowers of cannabis. In one embodiment, the naturally occurring concentration is the amount of terpenes in the crude extract of cannabis. In one embodiment, the non-naturally occurring concentration is measured by molarity and expressed as molarity. In one embodiment, the naturally occurring concentration is measured by mass percent.

as used herein, the term "non-naturally occurring concentration" refers to the amount of one or more compounds relative to the entire sample in the artificial composition. In one embodiment, the non-naturally occurring concentration is the amount of cannabinoid relative to the total composition. In one embodiment, the non-naturally occurring concentration is the amount of terpene relative to the total composition. In one embodiment, the non-naturally occurring concentration is measured by molarity and expressed as molarity. In one embodiment, the non-naturally occurring concentration is measured by mass percentage.

As used herein, the term "total mass" refers to the total mass of a given reference sample. In one embodiment, the total mass is measured by molecular weight.

The term "pharmacological fingerprint" refers to a collection of data on the activity of a single cannabinoid or terpene, or any combination of cannabinoids and/or terpenes, at one or more targets in the human body, for example, cannabinoid receptors, for example, CB1, CB2, GPR55,5HT-1A, 5HT-2A, TRPV1, serotonin receptors or μ -opioid receptors. The compositions disclosed herein are generated using cells (e.g., pharmacological fingerprints) and/or clinical data to select and combine specific combinations of compounds with novel properties.

as used herein, the term "potency" refers to the efficacy, effect, activity, or effectiveness of a composition disclosed herein at a particular cellular receptor. In one embodiment, efficacy is measured by the response of the subject. In one embodiment, potency is measured by cellular reactivity of cannabinoids to receptors, such as CB1, CB2, GPR55,5HT-1A, 5HT-2A, TRPV1, serotonin receptors or μ -opioid receptors. In one embodiment, potency refers to EC 50. In one embodiment, efficacy refers to the magnitude of the response.

as used herein, the term "agonistic" refers to the action of a compound, agonist, activating receptor, and inducing a response. In one embodiment, the receptor is selected from the group consisting of CB1, CB2, GPR55,5HT-1A, 5HT-2A, TRPV1, serotonin receptor or mu-opioid receptor. In one embodiment, the agonist is a cannabinoid. In one embodiment, the agonist is a terpene.

As used herein, the term "antagonism" refers to a combination of two or more compounds that has an effect. In one embodiment, the antagonism is a composition comprising a cannabinoid that affects another cannabinoid, i.e., a cannabinoid that affects binding of the other cannabinoid to a receptor. In one embodiment, the antagonism is a composition comprising a terpene that affects another cannabinoid, i.e., a terpene that affects the binding of another cannabinoid to a receptor.

In one embodiment, the compositions disclosed herein alter the potency of endogenous neurotransmitters in an organism, e.g., serotonin receptors, adrenergic receptors, dopamine receptors, gabaergic receptors, glutamatergic receptors, histaminergic receptors, cholinergic receptors, opioid receptors, glycinergic receptors, etc., at one or more of its endogenous receptors, e.g., serotonin, norepinephrine, epinephrine, dopamine, etc.

In one embodiment, the compositions disclosed herein increase serotonin-on-5-HT_1AThe potency of the receptor. In one embodiment, the compositions disclosed herein increase serotonin-on-5-HT_2AThe potency of the receptor. In one embodiment, the compositions disclosed herein increase serotonin-on-5-HT_1AReceptor potency and reduced serotonin-on-5-HT_2AThe potency of the receptor. In one embodiment, the compositions disclosed herein reduce serotonin on 5-HT_1Areceptor potency and increased serotonin-on-5-HT_2AThe potency of the receptor.

For example, the formulations of the present disclosure are achieved by: human components of the endocannabinoid system (or other known targets of cannabis pharmacology) are expressed in cultured cells and the cells are treated with serial dilutions of individual compounds or combinations of compounds to determine the EC50 of each component individually for each target, and whether addition of other components will alter the magnitude of the response or the effective concentration of the response (EC 50).

As used herein, the term "EC 50" means "half maximal effective concentration" which refers to the concentration of an agent (e.g., a cannabinoid, a terpene, or a combination thereof) that induces a response halfway between the baseline and the maximum after a specified exposure time. In one embodiment, the EC50 value is used as a measure of drug efficacy.

EC50 of the fractionated dose response curve represents the concentration of the compound in which 50% of its maximal effect was observed. EC50 of the quantum dose response curve represents the concentration of compound at which 50% of the population exhibited a response after the specified duration of exposure.

As used herein, the term "response amplitude" refers to the magnitude of reactivity to a composition disclosed herein. In one embodiment, the magnitude of the response is a response of a receptor, e.g., CB1, CB2, GPR55,5HT-1A, 5HT-2A, TRPV1, serotonin receptor, or μ -opioid receptor, to a sample administered thereto.

For example, in one system, D9-THC activity of cannabinoid receptor 1(CB1) has about 1 micromolar consistent EC50 and 40-50% response amplitude compared to the known, synthetic full agonist (CP-55,940). The lower response of CB1 to THC relative to full agonists is responsible for the fact that THC is known as a "partial agonist" of the CB1 receptor.

In some embodiments, the purposefully designed formulations disclosed herein are developed by establishing EC50 of THC multiple times in CB1 and determining EC50 of THC in a background of constant concentrations of other cannabinoids and terpenes. This is one example of a method for determining how a particular cannabis ingredient synergizes, adds or competes with the THC response itself.

The use of these purposefully designed combinations (rather than naturally occurring ones) provides the user with quantitative control over the underlying pharmacology and biochemistry that is responsible for the physical and psychological effects observed. Thus, the compositions disclosed herein provide unprecedented control over the effects of cannabinoids and/or terpenes on the user.

In one embodiment, the composition reduces EC50 for either or both of the first purified cannabinoid and/or the second purified cannabinoid for the particular receptor.

In one embodiment, the composition provides an increase in EC50 for either or both of a specific receptor, e.g., CB1, CB2, GPR55,5HT-1A, 5HT-2A, TRPV1, and/or a first purified cannabinoid and/or a second purified cannabinoid, for a mu-opioid receptor.

In one example, the compositions disclosed herein alter the EC50 of THC at the CB1 receptor. In one embodiment, the EC50 of THC is modulated, providing new beneficial properties, by using the synergistic compositions disclosed herein.

In one example, the THC activity of the CB1 receptor has about 1 micromolar consistent EC50 and 40-50% response amplitude compared to known, synthetic full agonists (e.g., CP-55,940).

In one example, the synergistic benefit of the compositions disclosed herein can be demonstrated by measuring the EC50 of THC alone at CB1 and then comparing it to the EC50 of THC at CB1 in the presence of other cannabinoids and terpenes.

In one example, the disclosed compositions provide a synergistic effect relative to a reference cannabinoid administered alone. In one example, the disclosed compositions increase the effect of the reference cannabinoid. In one example, the disclosed compositions compete with reference cannabinoids of the CB1 receptor.

In one example, the disclosed compositions provide a synergistic effect with respect to THC alone.

In one example, the disclosed compositions increase the effect of THC alone.

accordingly, the compositions disclosed herein provide a method of increasing the response of THC at the CB1 receptor (relative to THC alone), comprising administering THC with a terpene.

In one embodiment, the purified terpene is selected from limonene, nerolidol, β -myrcene, linalool, α -caryophyllene, β -caryophyllene, α -pinene, β -pinene, α -bisabolol, δ -3-carene, borneol, p-cymene, eucalyptol, α -humulene, α -terpineol, terpinolene, pulegone, camphene or geraniol.

Disclosed herein are methods of increasing the potency of a first purified cannabinoid, along with a first purified terpene, on a receptor, e.g., CB1, CB2 GPR55,5HT-1A, 5HT-2A, TRPV1, serotonin receptors, μ -opioid receptors, and the like. In one embodiment, increasing potency at the receptor comprises a second purified cannabinoid. In one embodiment, increasing the potency against the receptor comprises a second purified terpene.

In one embodiment, the compositions disclosed herein provide a method of increasing the response of THC at the CB1 receptor (relative to THC alone), comprising administering THC with a terpene. In one example, a method of increasing THC efficacy comprises administering THC with alpha-humulene. In one example, a method of increasing the efficacy of THC comprises administering THC with linalool. In one example, a method of increasing the efficacy of THC comprises administering THC with nerolidol. In one example, a method of increasing the efficacy of THC comprises administering THC with limonene. In one example, a method of increasing the efficacy of THC comprises administering THC with alpha terpineol. In one example, a method of increasing the efficacy of THC comprises administering THC with β -pinene. In one example, a method of increasing the efficacy of THC comprises administering THC with p-cymene. In one example, a method of increasing the efficacy of THC comprises administering THC with eucalyptol.

In one embodiment, the compositions disclosed herein provide a method of increasing the response of THC at the CB1 receptor (relative to THC alone), comprising administering THC with a second cannabinoid. In one example, a method of increasing the efficacy of THC comprises administering THC with CBC. In one example, a method of increasing the efficacy of THC comprises administering THC with CBG. In one example, a method of increasing the efficacy of THC comprises administering THC with THCV. In one example, a method of increasing the efficacy of THC comprises administering THC with a CBD.

In one example, the disclosed compositions compete with TH1 at the CB1 receptor.

In one example, the EC50 of THC at CB1 (relative to THC alone) is reduced by formulating a composition comprising purified THC and a purified terpene selected from limonene, nerolidol, β -myrcene, linalool, α -caryophyllene, β -caryophyllene, α -pinene, β -pinene, α -bisabolol, δ -3-carene, borneol, p-cymene, eucalyptol, α -humulene, α -terpinol, terpinolene, pulegone, camphene, or geraniol.

In one example, the EC50 of THC at CB1 (relative to THC alone) was increased by formulating a composition comprising purified THC and β -caryophyllene.

In one embodiment of the compositions disclosed herein, the phrase "comprising purified THC and purified terpene" means that the composition comprises a combined terpene content of from about 0.5% to about 10%.

An exemplary, non-limiting terpene is linalool. One embodiment of the present disclosure comprises 0.5-1% purified linalool. One embodiment of the present disclosure comprises 1-2% purified linalool. One embodiment of the present disclosure comprises 2-5% purified linalool. One embodiment of the present disclosure comprises 5-10% purified linalool.

in one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified limonene.

in one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified nerolidol.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified beta-myrcene.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified linalool.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified α -caryophyllene.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified β -caryophyllene.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified alpha-pinene.

in one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified β -pinene.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified α -bisabolol.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified delta-3-carene.

in one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified borneol.

in one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified eucalyptol.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified alpha-terpineol.

in one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified p-cymene.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified alpha-humulene.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified terpinolene.

in one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified pulegone.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified camphene.

In one example, the EC50 of THC at CB1 is reduced by formulating a composition comprising purified THC and purified geraniol.

In one example, the disclosed compositions increase the EC50 of a first cannabinoid at CB1, while increasing the EC50 of a second cannabinoid at CB 2.

In one example, the disclosed compositions increase EC50 of a first cannabinoid at CB1, while increasing EC50 of a second cannabinoid at GPR 55.

In one example, the disclosed compositions increase the EC50 of the first cannabinoid at CB1, while increasing the EC50 of the second cannabinoid at 5 HT-1A.

in one example, the disclosed compositions increase the EC50 of the first cannabinoid at CB1, while increasing the EC50 of the second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions increase the EC50 of the first cannabinoid at CB1 while decreasing the EC50 of the second cannabinoid at CB 2.

In one example, the disclosed compositions increase the EC50 of the first cannabinoid at CB1 while decreasing the EC50 of the second cannabinoid at GPR 55.

In one example, the disclosed compositions increase the EC50 of the first cannabinoid at CB1 while decreasing the EC50 of the second cannabinoid at 5 HT-1A.

In one example, the disclosed compositions increase the EC50 of the first cannabinoid at CB1 while decreasing the EC50 of the second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions increase the EC50 of a first cannabinoid at CB2, while increasing the EC50 of a second cannabinoid at CB 1.

In one example, the disclosed compositions increase EC50 of a first cannabinoid at CB2, while increasing EC50 of a second cannabinoid at GPR 55.

In one example, the disclosed compositions increase the EC50 of the first cannabinoid at CB2, while increasing the EC50 of the second cannabinoid at 5 HT-1A.

In one example, the disclosed compositions increase the EC50 of the first cannabinoid at CB2, while increasing the EC50 of the second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions increase the EC50 of the first cannabinoid at CB2 while decreasing the EC50 of the second cannabinoid at CB 1.

In one example, the disclosed compositions increase the EC50 of the first cannabinoid at CB2 while decreasing the EC50 of the second cannabinoid at GPR 55.

in one example, the disclosed compositions increase the EC50 of the first cannabinoid at CB2 while decreasing the EC50 of the second cannabinoid at 5 HT-1A.

In one example, the disclosed compositions increase the EC50 of the first cannabinoid at CB2 while decreasing the EC50 of the second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions increase the EC50 of a first cannabinoid at GPR55, while increasing the EC50 of a second cannabinoid at CB 1.

In one example, the disclosed compositions increase the EC50 of a first cannabinoid at GPR55, while increasing the EC50 of a second cannabinoid at CB 2.

In one example, the disclosed compositions increase the EC50 of a first cannabinoid at GPR55, while increasing the EC50 of a second cannabinoid at 5 HT-1A.

in one example, the disclosed compositions increase the EC50 of a first cannabinoid at GPR55, while increasing the EC50 of a second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions increase the EC50 of the first cannabinoid at GPR55 while decreasing the EC50 of the second cannabinoid at CB 1.

In one example, the disclosed compositions increase the EC50 of the first cannabinoid at GPR55 while decreasing the EC50 of the second cannabinoid at CB 2.

in one example, the disclosed compositions increase the EC50 of the first cannabinoid at GPR55 while decreasing the EC50 of the second cannabinoid at 5 HT-1A.

In one example, the disclosed compositions increase the EC50 of the first cannabinoid at GPR55 while decreasing the EC50 of the second cannabinoid at 5 HT-2A.

in one example, the disclosed compositions increase the EC50 of a first cannabinoid at 5HT-1A while increasing the EC50 of a second cannabinoid at CB 1.

in one example, the disclosed compositions increase the EC50 of a first cannabinoid at 5HT-1A while increasing the EC50 of a second cannabinoid at CB 2.

in one example, the disclosed compositions increase EC50 of a first cannabinoid at 5HT-1A while increasing EC50 of a second cannabinoid at GPR 55.

In one example, the disclosed compositions increase the EC50 of a first cannabinoid at 5HT-1A, while increasing the EC50 of a second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions increase the EC50 of the first cannabinoid at 5HT-1A while decreasing the EC50 of the second cannabinoid at CB 1.

In one example, the disclosed compositions increase the EC50 of the first cannabinoid at 5HT-1A while decreasing the EC50 of the second cannabinoid at CB 2.

In one example, the disclosed compositions increase EC50 of a first cannabinoid at 5HT-1A while decreasing EC50 of a second cannabinoid at GPR 55.

In one example, the disclosed compositions increase the EC50 of a first cannabinoid at 5HT-1A while decreasing the EC50 of a second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions increase the EC50 of a first cannabinoid at 5HT-2A while increasing the EC50 of a second cannabinoid at CB 1.

In one example, the disclosed compositions increase the EC50 of a first cannabinoid at 5HT-2A while increasing the EC50 of a second cannabinoid at CB 2.

In one example, the disclosed compositions increase EC50 of a first cannabinoid at 5HT-2A while increasing EC50 of a second cannabinoid at GPR 55.

In one example, the disclosed compositions increase the EC50 of a first cannabinoid at 5HT-2A, while increasing the EC50 of a second cannabinoid at 5 HT-1A.

In one example, the disclosed compositions increase the EC50 of the first cannabinoid at 5HT-2A while decreasing the EC50 of the second cannabinoid at CB 1.

in one example, the disclosed compositions increase the EC50 of the first cannabinoid at 5HT-2A while decreasing the EC50 of the second cannabinoid at CB 2.

in one example, the disclosed compositions increase EC50 of a first cannabinoid at 5HT-2A while decreasing EC50 of a second cannabinoid at GPR 55.

In one example, the disclosed compositions increase the EC50 of a first cannabinoid at 5HT-2A while decreasing the EC50 of a second cannabinoid at 5 HT-1A.

in one example, the disclosed compositions decrease the EC50 of a first cannabinoid at CB1 while increasing the EC50 of a second cannabinoid at CB 2.

In one example, the disclosed compositions decrease the EC50 of the first cannabinoid at CB1 while increasing the EC50 of the second cannabinoid at GPR 55.

In one example, the disclosed compositions lower the EC50 of the first cannabinoid at CB1 while increasing the EC50 of the second cannabinoid at 5 HT-1A.

In one example, the disclosed compositions lower the EC50 of the first cannabinoid at CB1 while increasing the EC50 of the second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at CB1 while reducing the EC50 of a second cannabinoid at CB 2.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at CB1 while reducing the EC50 of a second cannabinoid at GPR 55.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at CB1 while reducing the EC50 of a second cannabinoid at 5 HT-1A.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at CB1 while reducing the EC50 of a second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions decrease the EC50 of a first cannabinoid at CB2 while increasing the EC50 of a second cannabinoid at CB 1.

in one example, the disclosed compositions decrease the EC50 of the first cannabinoid at CB2 while increasing the EC50 of the second cannabinoid at GPR 55.

In one example, the disclosed compositions lower the EC50 of the first cannabinoid at CB2 while increasing the EC50 of the second cannabinoid at 5 HT-1A.

In one example, the disclosed compositions lower the EC50 of the first cannabinoid at CB2 while increasing the EC50 of the second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at CB2 while reducing the EC50 of a second cannabinoid at CB 1.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at CB2 while reducing the EC50 of a second cannabinoid at GPR 55.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at CB2 while reducing the EC50 of a second cannabinoid at 5 HT-1A.

in one example, the disclosed compositions reduce the EC50 of a first cannabinoid at CB2 while reducing the EC50 of a second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions decrease the EC50 of a first cannabinoid at GPR55 while increasing the EC50 of a second cannabinoid at CB 1.

In one example, the disclosed compositions decrease the EC50 of a first cannabinoid at GPR55 while increasing the EC50 of a second cannabinoid at CB 2.

In one example, the disclosed compositions decrease the EC50 of a first cannabinoid at GPR55 while increasing the EC50 of a second cannabinoid at 5 HT-1A.

in one example, the disclosed compositions decrease the EC50 of a first cannabinoid at GPR55 while increasing the EC50 of a second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at GPR55 while reducing the EC50 of a second cannabinoid at CB 1.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at GPR55 while reducing the EC50 of a second cannabinoid at CB 2.

in one example, the disclosed compositions reduce the EC50 of a first cannabinoid at GPR55 while reducing the EC50 of a second cannabinoid at 5 HT-1A.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at GPR55 while reducing the EC50 of a second cannabinoid at 5 HT-2A.

in one example, the disclosed compositions reduce the EC50 of the first cannabinoid at 5HT-1A while increasing the EC50 of the second cannabinoid at CB 1.

in one example, the disclosed compositions reduce the EC50 of the first cannabinoid at 5HT-1A while increasing the EC50 of the second cannabinoid at CB 2.

in one example, the disclosed compositions decrease EC50 of a first cannabinoid at 5HT-1A while increasing EC50 of a second cannabinoid at GPR 55.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at 5HT-1A while increasing the EC50 of a second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at 5HT-1A while reducing the EC50 of a second cannabinoid at CB 1.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at 5HT-1A while reducing the EC50 of a second cannabinoid at CB 2.

in one example, the disclosed compositions reduce the EC50 of a first cannabinoid at 5HT-1A while reducing the EC50 of a second cannabinoid at GPR 55.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at 5HT-1A while reducing the EC50 of a second cannabinoid at 5 HT-2A.

in one example, the disclosed compositions reduce the EC50 of the first cannabinoid at 5HT-2A while increasing the EC50 of the second cannabinoid at CB 1.

In one example, the disclosed compositions reduce the EC50 of the first cannabinoid at 5HT-2A while increasing the EC50 of the second cannabinoid at CB 2.

In one example, the disclosed compositions decrease EC50 of a first cannabinoid at 5HT-2A while increasing EC50 of a second cannabinoid at GPR 55.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at 5HT-2A while increasing the EC50 of a second cannabinoid at 5 HT-1A.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at 5HT-2A while reducing the EC50 of a second cannabinoid at CB 1.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at 5HT-2A while reducing the EC50 of a second cannabinoid at CB 2.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at 5HT-2A while reducing the EC50 of a second cannabinoid at GPR 55.

In one example, the disclosed compositions reduce the EC50 of a first cannabinoid at 5HT-2A while reducing the EC50 of a second cannabinoid at 5 HT-1A.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified limonene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified nerolidol.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified beta-myrcene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified linalool.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified α -caryophyllene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified β -caryophyllene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified alpha-pinene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified β -pinene.

in one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified α -bisabolol.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified delta-3-carene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified borneol.

in one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified eucalyptol.

In one example, the magnitude of the response of THC at CB1 was reduced by formulating a composition comprising purified THC and purified alpha terpineol.

In one example, the magnitude of the response of THC in CB1 is reduced by formulating a composition comprising purified THC and purified p-cymene.

In one example, the amplitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified alpha-humulene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified terpinolene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified camphene.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified geraniol.

In one example, the magnitude of the response of THC at CB1 is reduced by formulating a composition comprising purified THC and purified pulegone.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified limonene.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified nerolidol.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified beta-myrcene.

in one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified linalool.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified α -caryophyllene.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified β -caryophyllene.

in one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified alpha-pinene.

in one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified β -pinene.

in one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified α -bisabolol.

In one example, the magnitude of the response of THC at CB1 was increased by formulating a composition comprising purified THC and purified delta-3-carene.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified borneol.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified eucalyptol.

In one example, the magnitude of the response of THC at CB1 was increased by formulating a composition comprising purified THC and purified alpha terpineol.

in one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified p-cymene.

In one example, the amplitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified alpha-humulene.

In one example, the magnitude of the THC response at CB1 is increased by formulating a composition comprising purified THC and purified camphene.

In one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified terpinolene.

in one example, the magnitude of the response of THC at CB1 is increased by formulating a composition comprising purified THC and purified geraniol.

in one example, the magnitude of the response of THC at CB1 was increased by formulating a composition comprising purified THC and purified pulegone.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at CB1 while increasing the magnitude of the response of a second cannabinoid at CB 2.

in one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at CB1 while increasing the magnitude of the response of a second cannabinoid at GPR 55.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at CB1 while increasing the magnitude of the response of a second cannabinoid at 5 HT-1A.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at CB1 while increasing the magnitude of the response of a second cannabinoid at 5 HT-2A.

in one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at CB1 while decreasing the magnitude of the response of a second cannabinoid at CB 2.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at CB1 while decreasing the magnitude of the response of a second cannabinoid at GPR 55.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at CB1 while decreasing the magnitude of the response of a second cannabinoid at 5 HT-1A.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at CB1 while decreasing the magnitude of the response of a second cannabinoid to 5 HT-2A.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at CB2 while increasing the magnitude of the response of a second cannabinoid at CB 1.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at CB2 while increasing the magnitude of the response of a second cannabinoid at GPR 55.

in one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at CB2 while increasing the magnitude of the response of a second cannabinoid at 5 HT-1A.

in one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at CB2 while increasing the magnitude of the response of a second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at CB2 while decreasing the magnitude of the response of a second cannabinoid at CB 1.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at CB2 while decreasing the magnitude of the response of a second cannabinoid at GPR 55.

in one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at CB2 while decreasing the magnitude of the response of a second cannabinoid at 5 HT-1A.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at CB2 while decreasing the magnitude of the response of a second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid in GPR55 while increasing the magnitude of the response of a second cannabinoid in CB 1.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid in GPR55 while increasing the magnitude of the response of a second cannabinoid in CB 2.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid in GPR55 while increasing the magnitude of the response of a second cannabinoid in 5 HT-1A.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid in GPR55 while increasing the magnitude of the response of a second cannabinoid in 5 HT-2A.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid in GPR55 while decreasing the magnitude of the response of a second cannabinoid in CB 1.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid in GPR55 while decreasing the magnitude of the response of a second cannabinoid in CB 2.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid in GPR55 while decreasing the magnitude of the response of a second cannabinoid in 5 HT-1A.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid in GPR55 while decreasing the magnitude of the response of a second cannabinoid in 5 HT-2A.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at 5HT-1A while increasing the magnitude of the response of a second cannabinoid at CB 1.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at 5HT-1A while increasing the magnitude of the response of a second cannabinoid at CB 2.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at 5HT-1A while increasing the magnitude of the response of a second cannabinoid at GPR 55.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at 5HT-1A while increasing the magnitude of the response of a second cannabinoid at 5 HT-2A.

in one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at 5HT-1A while decreasing the magnitude of the response of a second cannabinoid at CB 1.

in one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at 5HT-1A while decreasing the magnitude of the response of a second cannabinoid at CB 2.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at 5HT-1A while decreasing the magnitude of the response of a second cannabinoid at GPR 55.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at 5HT-1A while decreasing the magnitude of the response of a second cannabinoid at 5 HT-2A.

in one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at 5HT-2A while increasing the magnitude of the response of a second cannabinoid at CB 1.

in one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at 5HT-2A while increasing the magnitude of the response of a second cannabinoid at CB 2.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at 5HT-2A while increasing the magnitude of the response of a second cannabinoid at GPR 55.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at 5HT-2A while increasing the magnitude of the response of a second cannabinoid at 5 HT-1A.

in one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at 5HT-2A while decreasing the magnitude of the response of a second cannabinoid at CB 1.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at 5HT-2A while decreasing the magnitude of the response of a second cannabinoid at CB 2.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at 5HT-2A while decreasing the magnitude of the response of a second cannabinoid at GPR 55.

In one example, the disclosed compositions increase the magnitude of the response of a first cannabinoid at 5HT-2A while decreasing the magnitude of the response of a second cannabinoid at 5 HT-1A.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at CB1 while increasing the magnitude of the response of a second cannabinoid at CB 2.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at CB1 while increasing the magnitude of the response of a second cannabinoid at GPR 55.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at CB1 while increasing the magnitude of the response of a second cannabinoid at 5 HT-1A.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at CB1 while increasing the magnitude of the response of a second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at CB1 while reducing the magnitude of the response of a second cannabinoid at CB 2.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at CB1 while reducing the magnitude of the response of a second cannabinoid at GPR 55.

in one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at CB1 while reducing the magnitude of the response of a second cannabinoid at 5 HT-1A.

in one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at CB1 while reducing the magnitude of the response of a second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at CB2 while increasing the magnitude of the response of a second cannabinoid at CB 1.

in one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at CB2 while increasing the magnitude of the response of a second cannabinoid at GPR 55.

in one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at CB2 while increasing the magnitude of the response of a second cannabinoid at 5 HT-1A.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at CB2 while increasing the magnitude of the response of a second cannabinoid at 5 HT-2A.

in one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at CB2 while reducing the magnitude of the response of a second cannabinoid at CB 1.

in one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at CB2 while reducing the magnitude of the response of a second cannabinoid at GPR 55.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at CB2 while reducing the magnitude of the response of a second cannabinoid at 5 HT-1A.

in one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at CB2 while reducing the magnitude of the response of a second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid in GPR55 while increasing the magnitude of the response of a second cannabinoid in CB 1.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid in GPR55 while increasing the magnitude of the response of a second cannabinoid in CB 2.

In one example, the disclosed compositions decrease the magnitude of the response of a first cannabinoid in GPR55 while increasing the magnitude of the response of a second cannabinoid in 5 HT-1A.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid in GPR55 while increasing the magnitude of the response of a second cannabinoid in 5 HT-2A.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid in GPR55 while reducing the magnitude of the response of a second cannabinoid in CB 1.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid in GPR55 while reducing the magnitude of the response of a second cannabinoid in CB 2.

in one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid in GPR55 while reducing the magnitude of the response of a second cannabinoid in 5 HT-1A.

in one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid in GPR55 while reducing the magnitude of the response of a second cannabinoid in 5 HT-2A.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at 5HT-1A while increasing the magnitude of the response of a second cannabinoid at CB 1.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at 5HT-1A while increasing the magnitude of the response of a second cannabinoid at CB 2.

in one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at 5HT-1A while increasing the magnitude of the response of a second cannabinoid at GPR 55.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at 5HT-1A while increasing the magnitude of the response of a second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at 5HT-1A while reducing the magnitude of the response of a second cannabinoid at CB 1.

in one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at 5HT-1A while reducing the magnitude of the response of a second cannabinoid at CB 2.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at 5HT-1A while reducing the magnitude of the response of a second cannabinoid at GPR 55.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at 5HT-1A while reducing the magnitude of the response of a second cannabinoid at 5 HT-2A.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at 5HT-2A while increasing the magnitude of the response of a second cannabinoid at CB 1.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at 5HT-2A while increasing the magnitude of the response of a second cannabinoid at CB 2.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at 5HT-2A while increasing the magnitude of the response of a second cannabinoid at GPR 55.

in one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at 5HT-2A while increasing the magnitude of the response of a second cannabinoid at 5 HT-1A.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at 5HT-2A while reducing the magnitude of the response of a second cannabinoid at CB 1.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at 5HT-2A while reducing the magnitude of the response of a second cannabinoid at CB 2.

in one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at 5HT-2A while reducing the magnitude of the response of a second cannabinoid at GPR 55.

In one example, the disclosed compositions reduce the magnitude of the response of a first cannabinoid at 5HT-2A while reducing the magnitude of the response of a second cannabinoid at 5 HT-1A.

In one example of the above embodiment, in a composition comprising THC and alpha-humulene, the THC is reduced at EC50 of CB 1.

in one embodiment, the THC is reduced to between about 0.1 micromolar to about 0.5 micromolar at EC50 of CB 1.

in an example of the above embodiment, in a composition comprising THC and linalool, the THC has a reduction in EC50 of CB 1.

In one embodiment, the THC is reduced to between about 0.05 micromolar to about 0.2 micromolar at EC50 of CB 1.

the above examples of cellular effects may further be relevant to the results of clinical studies, such as those exemplified in this application.

As used herein, the term "cannabinoid" refers to compounds belonging to a class of secondary compounds commonly found in cannabis plants. In one embodiment, the cannabinoids are present in plants, such as cannabis plants, and are sometimes referred to as phytocannabinoids (phytocannabinoids). In one embodiment, the cannabinoids are found in mammals and are sometimes referred to as endocannabinoids. In one embodiment, the cannabinoids are prepared in a laboratory environment, sometimes referred to as synthetic cannabinoids. In one embodiment, the cannabinoid acts on a cellular receptor, such as a G-coupled protein receptor (e.g., serotonin receptor, cannabinoid receptor, TRPV1, opioid receptor, etc.), thereby eliciting a response to the brain or body. In one embodiment, the cannabinoids affect the activity of other compounds at one or more receptors by acting as agonists, partial agonists, inverse agonists, antagonists and the like.

In many cases, cannabinoids can be identified because their chemical name will contain the text string ". cannabis (canabi). in the name.

In the context of the present application, when referring to specific cannabinoids, each of the acid and/or decarboxylated forms is considered to be a single molecule and a mixture.

examples of cannabinoids include, but are not limited to, cannabigerolic acid (CBGA), cannabigerolic acid monomethyl ether (CBGAM), Cannabigerol (CBG), cannabigerol monomethyl ether (CBGM), cannabigerolic acid (CBGVA), Cannabigerol (CBGV), cannabichromenic acid (CBCA), cannabichromene (CBC), cannabichromenic acid (CBCVA), cannabichromene (CBCV), cannabidiolic acid (CBDA), Cannabidiol (CBD), cannabidiol monomethyl ether (CBDM), cannabidiol-C₄(CBD-C₄) Cannabidivarin diphenolic acid (CBDVA), Cannabidivarin (CBDV), cannabidiol (CBD-C)₁) Tetrahydrocannabinolic acid A (THCA-A), tetrahydrocannabinolic acid B (THCA-B), tetrahydrocannabinolic acid (THCA), Tetrahydrocannabinol (THC), tetrahydrocannabinolic acid C₄(THCA-C₄) Tetrahydrocannabinol C₄(THC-C₄) Tetrahydrocannabinolic acid (THCVA), Tetrahydrocannabivarin (THC)V), tetrahydrocannabinolic acid (THCA-C)₁) Tetrahydrocannabinol (THC-C)₁)，Δ⁷-cis-Isotetrahydrocannabivarin, Δ⁸-tetrahydrocannabinolic acid (Δ)⁸-THCA), cannabinoic acid (CBNDVA), Cannabinodiol (CBNDV), Δ⁸-tetrahydrocannabinol (Δ)⁸-THC)，Δ⁹-tetrahydrocannabinol (Δ)⁹-THC), cannabichromenic acid (CBLA), Cannabichromene (CBL), Cannabigerol (CBLV), cannabigerolic acid a (CBEA-a), cannabigerolic acid B (CBEA-B), Cannabigeropine (CBE), Cannabigeropine (CBEV), cannabigerolic acid (CBEVA), cannabigerolic acid (CBEA), cannabigerolic acid (CBLV), cannabigerolic acid (CBLVA), cannabinolic acid (CBNA), Cannabigerol (CBN), cannabinolic acid (CBNVA), cannabinol monomethyl ether (CBNM), cannabinol-C₄(CBN-C₄) sub-Cannabinol (CBV), cannabinol-C₂(CBN-C₂) Cannabinol (CBN-C)₁) Cannabidiol (CBND), cannabidiolic acid (CBNDA), Cannabidivarin (CBDV), Cannabidicarbone (CBT), 10-ethoxy-9-hydroxy-Delta^6a-tetrahydrocannabinol, 8, 9-dihydroxy-delta^6a(10a)-tetrahydrocannabinol (8, 9-Di-OH-CBT-C)₅) Dihydroxycannabidivarin (CBTV), ethoxy-dihydroxycannabidivarin (CBTVE), Dihydrocannabidivarin (DCBF), Cannabinoids (CBF), cannabichromanone (CBCN), Cannabidicarbocycloalkane (CBT), 10-oxo-Delta^6a(10a)-tetrahydrocannabinol (OTHC), Δ⁹-cis-tetrahydrocannabinol (cis-THC), canabispsol (cbr), 3,4,5, 6-tetrahydro-7-hydroxy- α -2-trimethyl-9-n-propyl-2, 6-methanol-2H-1-benzoxazocin-5-methanol (OH-iso-HHCV), trihydroxy- δ -9-tetrahydrocannabinol (trihoh-THC), kavain, epigallocatechin gallate, dodecane-2E, 4E,8Z, 10Z-tetraenoic acid isobutylamide, and dodecane-2E, 4E-dienoic acid isobutylamide.

in one embodiment, the purified cannabinoid is selected from THC, D9-THC, D8-THC, THCA, THCV, D8-THCV, D9-THCV, THCVA, CBD, CBDA, CBDV, CBDVA, CBC, CBCA, CBCV, CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND, CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEVA, CBL, CBEV, CBLV or CBLVA.

as used herein, the term "THC" refers to tetrahydrocannabinol and has the following structural formula:

In the context of the present disclosure, THC-containing compositions are formulated with other compounds to provide efficacy, controls, consistency, purity, etc. not previously available.

As used herein, the term "THCA" refers to tetrahydrocannabinolic acid and has the following structural formula:

Decarboxylation of THCA with heat, light, etc. forms THC, D8-THC, D9-THC and other potential cannabinoids. In the context of the present disclosure, THCA-containing compositions are formulated with other compounds to provide efficacy, control, consistency, purity, and the like, not previously available.

As used herein, the term "THCV" refers to tetrahydrocannabivarin and has the following structural formula:

in the context of the present disclosure, THCV-containing compositions are formulated with other compounds to provide efficacy, control, consistency, purity, and the like, not previously available.

As used herein, the term "THCVA" refers to tetrahydrocannabinolic acid and has the following structural formula:

Decarboxylation of THCVA with heat, light, etc. leads to the formation of THCV, D8-THCV, D9-THCV and other possible cannabinoid derivatives. In the context of the present disclosure, compositions comprising THCVA are formulated with other compounds to provide efficacy, controls, consistency, purity, etc. not previously available.

as used herein, the term "D8-THC" refers to delta-8-tetrahydrocannabinol and has the following structural formula:

In the context of the present disclosure, compositions comprising D8-THC are formulated with other compounds to provide efficacy, control, consistency, purity, and the like, not previously available.

As used herein, the term "D8-THCV" refers to delta-8-tetrahydrocannabivarin and has the following structural formula:

in the context of the present disclosure, compositions comprising D8-THCV are formulated with other compounds to provide efficacy, controls, consistency, purity, and the like, not previously available.

As used herein, the term "D9-THC" refers to delta-9-tetrahydrocannabinol and has the following structural formula:

In the context of the present disclosure, compositions comprising D9-THC are formulated with other compounds to provide efficacy, controls, consistency, purity, and the like, not previously available.

as used herein, the term "D9-THCV" refers to delta-9-tetrahydrocannabivarin and has the following structural formula:

in the context of the present disclosure, compositions comprising D9-THCV are formulated with other compounds to provide efficacy, controls, consistency, purity, and the like, not previously available.

as used herein, the term "CBD" refers to cannabidiol and has the following structural formula:

In the context of the present disclosure, compositions comprising CBD are formulated with other compounds to provide efficacy, control, consistency, purity, etc., not previously available.

As used herein, the term "CBDA" refers to cannabidiolic acid and has the following structural formula:

The CBDA is decarboxylated with heat, light, etc. to form CBD and possibly other cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBDA are formulated with other compounds to provide efficacy, control, consistency, purity, and the like, not previously available.

As used herein, the term "CBDV" refers to cannabidivarin and has the following structural formula:

In the context of the present disclosure, compositions comprising CBDV are formulated with other compounds to provide efficacy, controls, consistency, purity, etc., not previously available.

As used herein, the term "CBDVA" refers to cannabinoids and has the following structural formula:

the decarboxylation of CBDVA with heat, light, etc. forms CBDV and other possible cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBDVA are formulated with other compounds to provide efficacy, control, consistency, purity, etc., not previously available.

As used herein, the term "CBC" refers to cannabichromene and has the following structural formula:

in the context of the present disclosure, compositions comprising CBC are formulated with other compounds to provide efficacy, control, consistency, purity, etc., not previously available.

as used herein, the term "CBCA" refers to cannabichromenic acid and has the following structural formula:

The decarboxylation of CBCA with heat, light, etc. forms CBC and other possible cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBCA are formulated with other compounds to provide efficacy, control, consistency, purity, etc., not previously available.

As used herein, the term "CBCV" refers to sub-cannabichromene and has the following structural formula:

In the context of the present disclosure, compositions comprising CBCV are formulated with other compounds to provide efficacy, control, consistency, purity, etc., not previously available.

As used herein, the term "CBCVA" refers to sub-cannabichromenic acid and has the following structural formula:

the decarboxylation of CBCVA with heat, light, etc. forms CBCV and possibly other cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBCVA are formulated with other compounds to provide efficacy, control, consistency, purity, etc., not previously available.

As used herein, the term "CBG" refers to cannabigerol and has the following structural formula:

In the context of the present disclosure, compositions comprising CBG are formulated with other compounds to provide efficacy, control, consistency, purity, and the like, not previously available.

As used herein, the term "CBGA" refers to cannabigerolic acid and has the following structural formula:

the CBGA is decarboxylated with heat, light, etc. to form CBG and possibly other cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBGA are formulated with other compounds to provide efficacy, control, consistency, purity, etc., not previously available.

As used herein, the term "CBGV" refers to cannabigerol and has the following structural formula:

in the context of the present disclosure, compositions comprising CBGV are formulated with other compounds to provide efficacy, control, consistency, purity, etc. not previously available.

As used herein, the term "CBGVA" refers to cannabigerolic acid and has the following structural formula:

The CBGVA is decarboxylated with heat, light, etc. to form CBGV and possibly other cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBGVA are formulated with other compounds to provide efficacy, control, consistency, purity, etc. not previously available.

As used herein, the term "CBN" refers to cannabinol and has the following structural formula:

In the context of the present disclosure, compositions comprising CBN are formulated with other compounds to provide efficacy, control, consistency, purity, etc., not previously available.

as used herein, the term "CBNA" refers to cannabinolic acid and has the following structural formula:

The decarboxylation of CBNA with heat, light, etc. forms CBN and possibly other cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBNA are formulated with other compounds to provide efficacy, control, consistency, purity, and the like, not previously available.

As used herein, the term "CBNV" or "CBV" refers to sub-cannabinol and has the following structural formula:

In the context of the present disclosure, compositions comprising CBNV are formulated with other compounds to provide efficacy, control, consistency, purity, and the like, not previously available.

As used herein, the term "CBNVA" refers to cannabinolic acid and has the following structural formula:

the CBNVA is decarboxylated with heat, light, etc. to form CBNV and other possible cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBNVA are formulated with other compounds to provide efficacy, control, consistency, purity, etc., not previously available.

As used herein, the term "CBND" refers to cannabidiol and has the following structural formula:

in the context of the present disclosure, compositions comprising CBNDs are formulated with other compounds to provide efficacy, control, consistency, purity, and the like, not previously available.

as used herein, the term "CBNDA" refers to cannabidiolic acid and has the following structural formula:

CBNDA is decarboxylated with heat, light, etc. to form CBND and possibly other cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBNDA are formulated with other compounds to provide efficacy, control, consistency, purity, and the like, not previously available.

As used herein, the term "CBNDV" refers to cannabidiol and has the following structural formula:

In the context of the present disclosure, compositions comprising CBNDV are formulated with other compounds to provide efficacy, control, consistency, purity, and the like, not previously available.

As used herein, the term "CBNDVA" refers to cannabinoylic acid and has the following structural formula:

CBNDVA is decarboxylated with heat, light, etc. to form CBNDV and possibly other cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBNDVA are formulated with other compounds to provide efficacy, control, consistency, purity, etc. not previously available.

as used herein, the term "CBL" refers to cannabigerol and has the following structural formula:

In the context of the present disclosure, compositions comprising CBLs are formulated with other compounds to provide efficacy, control, consistency, purity, and the like, not previously available.

As used herein, the term "CBLA" refers to cannabichromenic acid and has the following structural formula:

CBLA is decarboxylated with heat, light, etc. to form CBL and other possible cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBLA are formulated with other compounds to provide efficacy, control, consistency, purity, and the like, not previously available.

as used herein, the term "CBLV" refers to sub-cannabinol and has the following structural formula:

In the context of the present disclosure, compositions comprising CBLV are formulated with other compounds to provide efficacy, control, consistency, purity, and the like, not previously available.

As used herein, the term "CBLVA" refers to a hypocannabinolic acid and has the following structural formula:

The CBLVA is decarboxylated with heat, light, etc. to form CBLV and possibly other cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBLVA are formulated with other compounds to provide previously unavailable efficacy, controls, consistency, purity, and the like.

As used herein, the term "CBE" refers to cannabigeropine and has the following structural formula:

in the context of the present disclosure, compositions comprising CBEs are formulated with other compounds to provide efficacy, controls, consistency, purity, and the like, not previously available.

As used herein, the term "CBEA" refers to cannabigerolic acid and has the following structural formula:

The decarboxylation of CBEA with heat, light, etc. results in the formation of CBE and other possible cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBEA are formulated with other compounds to provide efficacy, control, consistency, purity, and the like, not previously available.

As used herein, the term "CBEV" refers to sub-cannabigeropine and has the following structural formula:

In the context of the present disclosure, compositions comprising CBEVs are formulated with other compounds to provide efficacy, control, consistency, purity, and the like, not previously available.

as used herein, the term "CBEVA" refers to sub-cannabigeronic acid and has the following structural formula:

the CBEVA is decarboxylated with heat, light, etc. to form CBEV and other possible cannabinoid derivatives. In the context of the present disclosure, compositions comprising CBEVA are formulated with other compounds to provide efficacy, control, consistency, purity, etc. not previously available.

As used herein, the term "terpene" refers to a compound that is built on an isoprenoid structure or is produced by combining isoprene units, a 5 carbon structure. Terpenes are also associated with the production of odors in plants where terpenes are part of a class of secondary compounds. In one embodiment, the terpene is a hydrocarbon.

in the context of the present disclosure, the term "terpene" does not necessarily require 5 carbons or multiples of 5 carbons. It is understood that the reaction with isoprene units does not always result in terpenes containing all carbon atoms.

In the context of the present disclosure, the term "terpene" includes hemiterpenes, monoterpene alcohols, terpene esters, diterpenes, monoterpenes, polyterpenes, tetraterpenes, terpene oxides, sesterterpenes, sesquiterpenes, norisoprene, or derivatives thereof. And isomeric, enantiomeric or optically active derivatives.

Derivatives of terpenes include terpenoids, hemiterpenoids, monoterpenes, sesquiterpenes, sesterterpenoids, tripterterpenoids, tetraterpenoids, triterpenoids, tetraterpenoids, polyisoprenoids and steroids.

In the context of the present disclosure, the term terpene includes α - (alpha), β - (beta), γ - (gamma), oxo-, isomers, or any combination thereof.

examples of terpenes in the context of the present disclosure include: 7, 8-dihydro- α -ionone, 7, 8-dihydro- β -ionone, acetylanisole, acetic Acid, acetylcedrene, anethol, anisole, benzaldehyde, bergamotene (α -cis-bergamotene) (α -trans-bergamotene), bisabolol (β -bisabolol), α -bisabolol, borneol, bornyl acetate, Butyric Acid (Butanoic/Butyric Acid), cadinene (α -cadinene) (γ -cadinene), caffeic Acid, camphene, camphor, capsaicin, carene (δ -3-carene), humulene, carvacrol, d-carvone, levocarvone, α -caryophyllene, β -caryophyllene, caryophyllene oxide, cedrene (α -cedrene) (β -cedrene), cedrene epoxide (alpha-cedrene epoxide), cedrene, conine, chlorogenic acid, cinnamaldehyde, alpha-amyl cinnamaldehyde, alpha-hexyl cinnamaldehyde, cinnamic acid, cinnamyl alcohol, citronellal, citronellol, cryptopine, curcumene (alpha-curcumene) (gamma-curcumene), decanal, dehydroemetic rauwolfinol, diallyl disulfide, dihydroactinidiole, dimethyl disulfide, eicosane (eicosane/icosane), elemene (beta-elemene), estragole, ethyl acetate, ethyl cinnamate, ethyl maltol, eucalyptol/1, 8-cineole, eucalyptol (alpha-eucalyptol) (beta-eucalyptol) (gamma-eucalyptol), eugenol, euphol, farnesene, farnesol, fenchyl (beta-fenchyl), fenchyl ketone, geraniol, geranyl acetate, germacrene B, guaiazulene-1 (10), 11-diene, guaiacol, guaiene (α -guaiene), GUYURENE (α -GUYURENE), 7-methoxycoumarin, hexanal (Hexanaldehyde), hexanoic acid, humulene (α -humulene) (β -humulene), ionol (3-oxo- α -ionol) (β -ionol), ionone (α -ionone) (β -ionone), isocoryne, isoamyl acetate, isoamyl alcohol, isoamyl formate, isobornyl, isomyrcenol, isopulegol, isovaleric acid, isoprene, kahweol, lavender alcohol, limonene, γ -linolenic acid, linalool, longifolene, α -longifolene, limonene, d-linolenic acid, γ -linolenic acid, linalool, and α -longifolene, Lycopene, menthol, methyl butyrate, 3-mercapto-2-methylpentanal, thiol/thiol, beta-mercaptoethanol, thioglycolic acid, allyl thiol, benzyl thiol, butyl thiol, ethyl thiol, methyl thiol, furfuryl thiol, ethylene glycol thiol, propyl thiol, thiophenyl thiol, methyl salicylate, methyl butenol, methyl 2-methylpentanoate, methyl thiobutyrate, myrcene (beta-myrcene), gamma-ylarene, nepetalactone, nerol, nerolidol, neryl acetate, nonanal, nonanoic acid, ocimene, octanal, octanoic acid, p-cymene, amyl butyrate, phellandrene, phenylacetaldehyde, phenethyl thiol, phenylacetic acid, phytol, pinene, beta-pinene, propylthiol, patulin, pulegone, quercetin, retinol, rutin, sabinene, sabinene hydrate, cis-sabinene hydrate, trans-sabinene hydrate, safranal, alpha-apiene, alpha-sinenseal, beta-sitosterol, squalene, taxadiene, terpine hydrate, terpineol, terpinen-4-ol, alpha-terpinene, gamma-terpinene, terpinolene, thiophenol, thujone, thymol, alpha-tocopherol, coumarone undecanone, undecalanal, pentanal, o-tert-butylcyclohexyl acetate, alpha-ylacene, umbelliferone or vanillin.

As used herein, the term "7, 8-dihydro- α -ionone" refers to a compound having the following structural formula:

7, 8-dihydro- α -ionone is often characterized as having a woody, floral odor.

as used herein, the term "7, 8-dihydro- β -ionone" refers to a compound having the following structural formula:

7, 8-dihydro- β -ionone is often characterized as having a woody aroma.

as used herein, the term "acetoacetoxy" refers to a compound having the following structural formula:

Acetylanisole generally has a sweet, anisic, vanilla aroma with subtle differences in powder form, balsam and benzaldehyde. Acylanisole is also used as a flavoring agent.

as used herein, the term "acetic acid" refers to a compound having the following structural formula:

Acetic acid is generally characterized as one of the main components of vinegar.

As used herein, the term "acetylcedrene" refers to a compound having the following structural formula:

Acetylcedrene usually has a musk odour of warm, woody, amber colour. Acetylcedrene is also a perfume.

As used herein, the term "anethole" refers to an aromatic compound having the following structural formula:

Anethole usually has a sweet taste, an anise flavor, and a licorice flavor. Anethole is used for various essences and flavors.

As used herein, the term "anisole" refers to a compound having the following structural formula:

Anisole is generally characterized by smelling like fennel seed.

As used herein, the term "benzaldehyde" refers to a compound having the following structural formula:

Benzaldehyde generally has an odor similar to almond.

as used herein, the term "bergamotene" refers to a compound comprising one or both of α -cis-bergamotene and/or α -trans-bergamotene, either neat and/or in any proportion in a mixture.

Alpha-cis-bergamotene refers to a compound having the following structural formula:

Alpha-cis-bergamotene is generally characterized as having a strong black pepper odor. Alpha-cis-bergamotene is a flavor component of many species of the orchid family.

alpha-trans-bergamotene refers to the following structural formula:

Alpha-trans-bergamotene is generally characterized as having a moderate-intensity, warm, tea-like odor. Alpha-trans-bergamotene is used in the chemical communication system of certain classes of aphids.

As used herein, the term "bisabolol" refers to a compound comprising one or both of alpha-bisabolol and/or beta-bisabolol in pure and/or in any ratio in a mixture.

alpha-bisabolol refers to a compound having the following structural formula:

Alpha-bisabolol is generally characterized as an active ingredient in chamomile.

beta-bisabolol refers to a compound having the following structural formula:

Beta-bisabolol is generally characterized as having a citrus, floral, lemon, sweet, herbal aroma.

as used herein, the term "borneol" refers to a compound having the following structural formula:

borneol is generally characterized by having a menthol aroma, similar to camphor. Borneol can also be converted into camphor.

as used herein, the term "bornyl acetate" refers to a compound having the following structural formula:

Bornyl acetate is generally characterized by having a pine, camphor, herbal and balsamic odor.

As used herein, "butyric acid/butyric acid" refers to a compound having the following structural formula:

Butyric acid is generally characterized as having an unpleasant, pungent odor commonly found in sweat, flatulence and rancid butter.

as used herein, the term "cadinene" refers to a compound comprising one or both of alpha-cadinene and/or gamma-cadinene, either pure and/or in any proportion in a mixture.

Alpha-cadinene refers to a compound having the following structural formula:

Alpha-juniperbene terpenes are generally characterized as having pungent, smoky, woody, guaiac-like odors.

Gamma-cadinene refers to a compound having one of the following structural formulae:

OrGamma-cadinene is generally characterized by having herbal, woody aromas. Gamma-juniperbene terpene has some antimicrobial properties. Many species of termites and some beetles use gamma-cadinene in their chemical communication systems.

As used herein, the term "cafestol" refers to a compound having the following structural formula:

Cafestol is generally characterized as the major component of coffee.

as used herein, the term "caffeic acid" refers to a compound having the following structural formula:

Caffeic acid is often characterized as a key intermediate in lignin synthesis.

As used herein, the term "camphene" refers to a compound having the structural formula:

camphene is generally characterized by having a pungent, herbal, fir-leaf odor. Camphene is used in perfumes and food additives. Camphene is a minor component of many essential oils such as turpentine, cypress oil, camphor oil, citronella oil, neroli oil, ginger oil and valerian.

As used herein, the term "camphor" refers to a compound having one of the following structural formulae:

OrIn bookin the context of the disclosure, the term "camphor" includes enantiomers, either in single form or as mixtures in any proportion. Camphor has a very distinctive odor, which is known under the name of trees. Camphor is used as essence and flavor for chewing gum, hard candy, etc.

as used herein, the term "capsaicin" refers to a compound having the following structural formula:

Capsaicin is generally odorless. Capsaicin is generally characterized as an irritant to mammals, and its sensation upon inhalation, consumption or application to the skin is known.

as used herein, the term "carene" or "delta-3-carene" refers to a compound having the following structural formula:

delta-3-carene, sometimes referred to as "carene," is generally described as having a sweet and pungent odor.

As used herein, the term "humulene" refers to any of a series of related compounds having the chemical formula C40 Hx.

In the context of the present disclosure, the term "humulene" refers to any isomeric form of humulene in a mixture, pure and/or in any proportion. Humulene is generally characterized as an important compound in photosynthesis.

as used herein, the term "carvacrol" refers to a compound having the following structural formula:

carvacrol is generally characterized by an irritating odor of oregano. Carvacrol is often used as a flavor and fragrance, and its flavor is described as spicy, herbal, phenolic, medicinal, and woody.

As used herein, the term "dextrocarvone" refers to the S- (+) enantiomer of carvone having the following structural formula:

Dextrocarvone generally has a pungent, toasty and savory odor. Dextrocarvone is present in citrus peel oil and ginger oil. Dextrocarvone is the main component of oleum Rapae.

as used herein, the term "levocarvone" refers to the R- (-) enantiomer of carvone having the following structural formula:

Levocarvone is generally characterized as having a sweet, minty, herbal, and spearmint flavor. L-carvone is present in spearmint and sassafras macrocarpa oil.

As used herein, the term "β -caryophyllene" refers to a compound having the following structural formula:

Beta-caryophyllene is generally characterized by the flavor component of black pepper. Beta-caryophyllene is commonly referred to as caryophyllene.

As used herein, the term "caryophyllene oxide" refers to a compound having the following structural formula:

caryophyllene oxide is generally characterized as having a lemon balm odor.

As used herein, the term "cedrene" refers to either or both of alpha-cedrene and/or beta-cedrene, in pure form or as a mixture in any proportion.

Alpha-cedrene refers to a compound having the following structural formula:

Alpha-cedrene is generally characterized by a moderate-intensity, woody, sweet, fresh cedar aroma. Alpha-cedrene is used for bakery foods, fruit lotions and fruit sorbets. Alpha-cedrene is the main component in cedrene essential oil.

Beta-cedrene refers to a compound having the following structural formula:

Beta-cedrene is generally characterized by having the woody aroma of cedar. Beta-cedrene is the main component in cedar essential oil.

as used herein, the term "cedrene epoxide" or "α -cedrene epoxide" refers to a compound having the following structural formula:

Alpha-cedrene epoxides are generally characterized by having a woody, amber, tobacco, sandalwood and fresh patchouli odor. Alpha-cedrene epoxides are commonly used as fragrances and perfumes for cosmetics.

as used herein, the term "cedrol" refers to a compound having the following structural formula:

Cedrol is generally characterized as having a very weak aroma, sweetness, cedar and woody. Cedrol is the main component of cedar oil.

As used herein, the term "conirene a" refers to a compound having the following structural formula:

Cedrene A is generally characterized as having a weak waxy odour.

As used herein, the term "chlorogenic acid" refers to a compound having the following structural formula:

Chlorogenic acid is commonly found in extracts of peach, plum and green coffee beans.

As used herein, the term "cinnamaldehyde" refers to a compound having the following structural formula:

Cinnamaldehyde is generally characterized by a pungent, sweet cinnamon odor and imparts a cinnamon flavor. Cinnamaldehyde occurs naturally in the bark of the cinnamon tree and other species of the cinnamomum genus.

As used herein, the term "α -hexyl-cinnamaldehyde" refers to a compound having the following structural formula:

alpha-hexyl-cinnamaldehyde is generally characterized as having a sweet, floral, green, jasmine, citrus and fruit aroma, with a powdery, tropical or spicy taste.

As used herein, the term "α -pentyl-cinnamaldehyde" refers to a compound having the following structural formula:

Alpha-amyl-cinnamaldehyde is generally characterized as having a sweet, floral, fruity, herbal, jasmine, and tropical aroma.

As used herein, the term "cinnamic acid" refers to a compound having the following structural formula:

Cinnamic acid is generally characterised by having a balsamic, sweet, benzoin, honey-like odour. Cinnamic acid is derived from cinnamon oil or from balsams such as benzoin.

As used herein, the term "cinnamyl alcohol" refers to a compound having the following structural formula:

Cinnamyl alcohol is generally characterized by having cinnamon flavor, cyanine and fermentation odor, and powdery balsams nuances. As a flavor component, cinnamyl alcohol has a green, floral, spicy and honey taste with slight differences in yeast fermentation.

as used herein, the term "citronellal" refers to a compound having the following structural formula:

citronellal is generally characterized as accounting for up to 80% of the leaf oil from the leaf of lime california and as a characteristic aroma.

As used herein, the term "citronellol" refers to either or both of the (+) and (-) enantiomers, either in pure form or as a mixture in any proportion.

The (+) enantiomer has the following structural formula:

The (-) form has the following structural formula:

citronellol is usually floral, rose, sweet, citrus, with green, fatty, terpene subtle odor.

As used herein, the term "cryptopine" refers to a compound having the following structural formula:

Cryptopine generally has a woody mint herb odor.

as used herein, the term "curcumene" refers to either or both of alpha-curcumene and/or gamma-curcumene, either in pure form or as a mixture in any proportion.

α -curcumene has the following structural formula:

Alpha-curcumene is generally characterized as having a scent similar to that of turmeric. Alpha-curcumene is found mainly in the genus zingiber.

Gamma-curcumene has the following structural formula:

gamma-curcumene is generally characterized as having a mud odor. Gamma-curcumene is found mainly in the Begonis bidwillii tree of New Zealand.

As used herein, the term "decanal" refers to compounds having the following structural formula:

decanal is generally characterized as having a citrus odor. Decanal is used as a fragrance and a flavoring agent.

as used herein, the term "dehydrorauwolfia emethole" refers to a compound having the following structural formula:

dehydroemetic rauwolfia alcohol is generally characterized as having a fruity and floral aroma.

As used herein, the term "diallyl disulfide" refers to compounds having the following structural formula:

Diallyl disulfide is generally characterized by a strong, off-flavor onion and garlic-like odor.

As used herein, the term "dihydroactinidiolide" refers to a compound having the following structural formula:

dihydroactinidiolides are generally characterized as having a fruity, musk, coumarin tea-like, peach-like flavor.

As used herein, the term "dimethyldisulfide" refers to a compound having the following structural formula:

Dimethyl disulfide is generally characterized as having a sulfur-containing, decaying odor.

As used herein, the term "eicosane (eicosane)" or "eicosane (icosane)" refers to compounds of formula C₂₀H₄₂And has 366,619 constitutional isomers having the following skeleton structure:

Eicosane is generally characterized as having a waxy odor. Eicosane is used in flavor concentrates.

As used herein, the term "β -elemene" refers to a compound having the following structural formula:

Beta-elemene is generally characterized as having a sweet fragrance.

As used herein, the term "estragole" refers to a compound having the following structural formula:

Estragole is an isomer of anethole. Artemisin is generally characterized by an anise seed odor and is present in tarragon oil, turpentine and other essential oils.

As used herein, the term "ethyl acetate" refers to a compound having the following structural formula:

Ethyl acetate is generally characterized as having an acidic, fruity, foul, cheese, fermented odor.

As used herein, the term "ethyl cinnamate" refers to a compound having the following structural formula:

Ethyl cinnamate is generally characterized as having a sweet, savory, spicy, fruity, berry and plum flavor.

As used herein, the term "ethyl maltol" refers to a compound having the following structural formula:

Ethyl maltol is generally characterized as having a sweet taste similar to caramel and cooked fruit.

As used herein, the term "eucalyptol" refers to a terpene having the following structural formula:

Eucalyptol is generally characterized as having a minty taste. Eucalyptols are also known as 1, 8-cineole, eucalyptol, 1, 8-epoxy-p-menthane, 1, 8-oxy-p-menthane, eucalyptol, 1,3, 3-trimethyl-2-oxabicyclo [ 2.2.2 ] octane, eucalyptol and eucalyptol.

As used herein, the term "cineol" refers to alpha-cineol, beta-cineol or gamma-cineol as pure forms or mixtures in any proportion.

Alpha-cineol has the following structural formula:

Alpha-cineol is generally characterized as having a sweet, woody odor.

Beta-cineol has the following structural formula:

Beta-eucalyptol is generally characterized as having a sweet, green, woody, grapefruit-like aroma.

Gamma-cineol has the following structural formula:

Gamma-eucalyptol is generally characterized as having a waxy, sweet, woody and floral character.

As used herein, the term "eugenol" refers to a compound having the following structural formula:

Eugenol is generally characterized by the aroma that causes cloves. Eugenol is present in insect attractants and in ultraviolet absorbers.

as used herein, the term "euphadienol" refers to a compound having the following structural formula:

Euphadienol is generally characterised by being the major component in Euphorbia (Euphorbia tirucalli) juice.

As used herein, the term "farnesene" refers to six closely related compounds. (E, E) - α -farnesene is one of these six molecules and has the following structural formula:

In the context of the present disclosure, the term "farnesene" refers to any one of the six closely related compounds, alone or in combination with any other of the six closely related compounds. Farnesene is generally characterized by having the fragrance of magnolia, and has a citrus fragrance, with a green, woody, plant odor, with a light lavender odor.

as used herein, the term "farnesol" refers to a compound having the following structural formula:

farnesol is generally characterized as having a mild, fresh, sweet, floral, linden odor. Farnesol is used in cosmetics, perfumes and fragrances.

as used herein, the term "fenchyl alcohol" or "β -fenchyl alcohol" refers to a compound having the structural formula:

beta-fenchyl alcohol is generally characterized by having a camphor, pine, woody, dry, sweet, lemon flavor. Beta-fenchyl alcohol is used as a fragrance and flavor.

As used herein, the term "fenchone" refers to a compound having the following structural formula:

Fenchyl ketone is typically characterized by having a camphor, thuja, cedar leaf, herb, earth, woody aroma.

As used herein, the term "geraniol" refers to a compound having the following structural formula:

Geraniol is often characterized as having a sweet rose-like fragrance.

As used herein, the term "geranyl acetate" refers to a compound having the following structural formula:

Geranyl acetate is generally characterized as having a floral and fruity scent. Geranyl acetate is present in various natural oils from plants such as citronella, lemon grass, sassafras, roses, and many others.

As used herein, the term "geranyl farnesol" refers to a compound having the following structural formula:

Geranyl farnesol is generally characterized as a clear colorless liquid.

As used herein, the term "germacrene" refers to a class of hydrocarbons. In the context of the present disclosure, the term "germacrene" refers to any one of the five isomers, either in pure form or in any combination of the five isomers.

Germacrene A refers to the following structural formula:

Germacrene B refers to the following structural formula:

Germacrene C refers to the following structural formula:

Germacrene D refers to the following structural formula:

germacrene E refers to the following structural formula:

As used herein, the term "guaiacol-1 (10), 11-diene" refers to a compound having the following structural formula:

guaia-1 (10), 11-diene is generally characterized as having a sweet, woody aroma. Guaia-1 (10), 11-diene is used as a flavour in a variety of products ranging from food additives, tobacco flavourings and cosmetics in general to perfuming chambers.

As used herein, the term "guaiacol" refers to a compound having the following structural formula:

Guaiacol is generally characterized by having a smoky, spicy, woody, medicinal odor. Guaiacol has sweet, powdery, musty, vanilla, floral, almond notes.

As used herein, the term "α -guaiene" refers to a compound having the following structural formula:

Alpha-guaiene generally has a sweet, earthy, woody, balsamic, spicy aroma.

As used herein, the term "navene" or "alpha-navene" refers to a compound having the following structural formula:

Alpha-gulcene is generally characterized by having a woody, balsamic odor. Alpha-gulinene is used in cosmetics and perfumes.

As used herein, the term "deracinator" refers to a compound having the following structural formula:

delphinidin is commonly found in Herniaria (Herniaria glabra), eupatorium triloba (ayanpa tripliniervis), and species of the genus Prunus (Prunus) (mahaleib), Prunus binga (p.pensylvanica), and populus tremula (p.maximowiczil).

As used herein, the term "hexanal" refers to a compound having the following structural formula:

hexanal is generally characterized by having a grassy odor. Hexanal (Hexanaldehyde) is also known as hexanal (hexanal).

as used herein, the term "hexanoic acid" refers to a compound having the following structural formula:

Caproic acid is generally characterized by a cheese odor with pungent, spicy, sour, fatty, sweat, rancid.

As used herein, the term "alpha-humulene" refers to a compound having the following structural formula:

alpha-humulene is generally characterized as contributing to the flavor profile of beer. Alpha-humulene is sometimes often referred to simply as "humulene" or "caryophyllene," and in the context of this disclosure, the two are used interchangeably.

as used herein, the term "β -humulene" refers to a compound having the following structural formula:

beta-humulene is generally characterized as having a green aroma.

as used herein, the term "ionol" refers to a compound having the following structural formula:

Ionol is also known as Butylhydroxytoluene (BHT). For the purposes of this disclosure, "ionol" also refers to 3-oxo-alpha-ionol and/or beta-ionol in pure and/or in any proportion in the mixture. Ionol is generally characterized as having a sweet, woody, herbaceous, fruity, floral, tropical and berry aroma.

as used herein, the term "ionone" refers to either or both of alpha-ionone and/or beta-ionone as pure forms or mixtures in any proportion.

Alpha-ionone refers to the following structural formula:

Beta-ionone refers to the following structural formula:

Alpha-ionone and beta-ionone as a mixture have an aroma similar to that of violet flower.

as used herein, the term "ips dienol" refers to a compound having the following structural formula:

ips typographus is generally characterized by a scent of balsam, rosin.

As used herein, the term "isoamyl acetate" refers to a compound having the following structural formula:

Isoamyl acetate is generally characterized as having an odor similar to bananas and pears.

as used herein, the term "isoamyl alcohol" refers to a compound having the following structural formula:

isoamyl alcohol is generally characterized as having an irritating, fermented, fusel, alcohol-like aroma, with a fruity, banana and molasses flavor. Isoamyl alcohol is used as a flavor and fragrance.

As used herein, the term "isoamyl formate" refers to a compound having the following structural formula:

Isoamyl formate is generally characterized as having the aroma of wine, dry, earthy, fruity, green, plum and blackcurrant.

as used herein, the term "isoborneol" refers to a compound having the following structural formula:

Isoborneol is generally characterized as having camphor, sweet and musty taste.

As used herein, the term "isomyrcenol" refers to a compound having the following structural formula:

Isomyrcenol is generally characterized as having a fresh, floral, lime-like odor. Isomyrcenol is used in the chemical communication system of beetles.

as used herein, the term "isopulegol" refers to a compound having the following structural formula:

Isopulegol is generally characterized as having a moderately intense odor, namely peppermint, cool and bitter sweet. In the context of the present disclosure, "isopulegol" may also refer to any number of isomeric forms.

as used herein, the term "isovaleric acid" refers to a compound having the following structural formula:

Isovaleric acid is generally characterized by a cheese odor with strong, pungent, sour and sweat flavors. Isovaleric acid is also known as 3-methylbutyric acid.

As used herein, the term "isoprene" refers to a compound having the following structural formula:

Isoprene is generally characterized as a building block for many other terpenes.

as used herein, the term "kahweol" refers to a compound having the following structural formula:

As used herein, the term "lavender alcohol" means the R and S enantiomers are in pure form or in any ratio of mixtures, having the following structural formula:

lavenol is commonly found in lavender essential oil.

As used herein, the term "limonene" refers to a terpene having the following structural formula:

limonene is generally characterized as having an odor similar to orange and other citrus fruits. In the context of the present disclosure, the term "limonene" includes all possible enantiomers and isomers of a compound as an individual compound or as a racemic mixture.

As used herein, the term "gamma-linolenic acid" refers to a compound having the following structural formula:

gamma-linolenic acid is generally characterized by unsaturated fatty acids that are predominantly present in vegetable oils.

as used herein, the term "linalool" refers to a terpene having the following structural formula:

Linalool has two known enantiomeric forms. The (S) - (+) -linalool is generally characterized by sweetness and floral, whereas the (R) -form is more like wood and lavender. In the context of the present disclosure, "linalool" refers to a racemic mixture of either or both enantiomers.

As used herein, the term "longifolene" refers to a compound having (+) and (-) enantiomers. The (+) enantiomer refers to the following structural formula:

In the context of the present disclosure, the term "longifolene" refers to its (+) and/or (-) enantiomers in pure form or in mixtures in any proportion. Longifolene is generally characterized by a sweet, woody, rose, medicinal, fir needle-like odor.

as used herein, the term "α -longifolene" refers to a compound having the following structural formula:

Alpha-longifolene is generally characterized as having a rosin odor.

as used herein, the term "lycopene" refers to a compound having the following structural formula:

lycopene is generally characterized by its red color.

As used herein, the term "luteolin" refers to a compound having the following structural formula:

Luteolin is found in leaves, pericarp, bark, clover and ragweed pollen.

As used herein, the term "menthol" refers to a compound having the following structural formula:

Menthol is generally characterized by having cooling, mint aroma and flavor. Menthol is obtained from peppermint, peppermint or other mint oils.

As used herein, the term "methyl butyrate" refers to a compound having the following structural formula:

Methyl butyrate is generally characterized as having a sulfur-containing odor.

As used herein, the term "3-mercapto-2-methylpentanal" refers to a compound having the following structural formula:

The 3-mercapto-2-methylpentanal is generally characterized as having a sulphur-containing, garlic flavour, garlic odour.

as used herein, the term "3-mercapto-2-methylpentanol" refers to a compound having the following structural formula:

3-mercapto-2-methylpentanol is generally characterized as having a very strong, sulphur-containing, onion-type aroma.

as used herein, the term "thiol" refers to an organosulfur compound that contains a mercapto group bonded to carbon. Mercaptans are often characterized as being added to help detect the main odorous components of natural gas (which is odourless in its pure form), and the "smell of natural gas" is due to the smell of mercaptans used as odorants. Mercaptans (Mercaptan) are also known as thiols (thiol).

as used herein, the term "β -mercaptoethanol" refers to a compound having the following structural formula:

Beta-mercaptoethanol is generally characterized by an extremely strong and long-lasting sulfur aroma.

As used herein, the term "thioglycolic acid" refers to a compound having the following structural formula:

Thioglycolic acid is generally characterized as having ugly, sharp, harsh, malodorous and durable properties. Thioglycolic acid (Mercaptoacetic acid) is also known as thioglycolic acid (thioglycollic acid).

As used herein, the term "allylthiol" refers to a compound having the following structural formula:

allyl mercaptan is generally characterized as having a strong sulfur-containing and garlic-flavored aroma.

As used herein, the term "benzylthiol" refers to a compound having the following structural formula:

Benzylmercaptan is generally characterized as having a strong, sharp, garlic-like, sulfur-containing, onion, garlic and horseradish-like aroma.

the term "butylmercaptan," as used herein, refers to a compound having the following formula C₄H₁₀A compound of S. In one embodiment, the butyl mercaptan has the following structural formula:

In one embodiment, the butyl mercaptan has the following structural formula:

Butyl mercaptan is generally characterized as having a very strong malodorous odor, commonly referred to as a "skunk" odor.

as used herein, the term "methyl mercaptan" refers to a compound having the following structural formula:

Methyl mercaptan is generally characterized by an extremely strong, sulfur, decomposing cabbage, skunk odor. Methyl mercaptan (Methyl mercaptan) is also known as Methyl mercaptan (methanethiol).

As used herein, the term "furfuryl mercaptan" refers to a compound having the following structural formula:

Furfuryl mercaptan is generally characterized by a very strong, oily, fatty, sulfurous, skunk odor.

as used herein, the term "ethanedithiol" refers to a compound having the following structural formula:

Ethanedithiol is generally characterized by a very high-strength, sulfurous, skunk odor.

As used herein, the term "propyl thiol" refers to a compound having the following structural formula:

Propyl mercaptan is generally characterized as having a high strength, garlic, natural gas, sweet onion, cabbage odor. Propyl mercaptan is also known as propanethiol.

as used herein, the term "thiophenemethylthiol" refers to a compound having the following structural formula:

Thiophenemethylthiols are generally characterized as having a strong roasted coffee, fishy smell. Thiophenemethyl mercaptan is used as a flavor agent to mimic the flavor of coffee.

As used herein, the term "methyl salicylate" refers to a compound having the following structural formula:

Methyl salicylate is generally characterized as having a strong, noticeable wintergreen aroma. Methyl salicylate is used as an aromatic, food and beverage agent.

as used herein, the term "methylbutenol" refers to a compound having the following structural formula:

Methylbutenol is generally characterized as having a very strong malt herbal aroma. Methylbutenol is released from the twisted pine tree at a high concentration.

as used herein, the term "methyl 2-methylpentanoate" refers to a carboxylic acid having the following structural formula:

Methyl 2-methylpentanoate is generally characterized as having a fruity, sweet, berry, pineapple, apple, banana, green melon and tropical aroma.

As used herein, the term "methyl thiobutyrate" refers to a compound having the following structural formula:

methyl thiobutyrate is generally characterized as a flavoring agent and a food agent.

As used herein, the term "β -myrcene" refers to a terpene having the following structural formula:

Beta-myrcene is generally characterized by having a earthy, fruity syringy odor. Beta-myrcene is also known as "myrcene".

As used herein, the term "γ -menthalene" refers to a compound having the following structural formula:

gamma-menthene is generally characterized by having herbal, woody, and spicy aromas.

As used herein, the term "nepetalactone" refers to a compound having the structural formula:

nepetalactones are generally characterized as having a valerian odor. Nepetalactone is also one of the major attractants and stimulants in catnip, and when inhaled, it can recognize wild play behavior in many cats.

As used herein, the term "nerol" refers to a compound having the following structural formula:

Nerol is generally characterized as a fragrance ingredient in cosmetics and as a flavoring agent.

as used herein, the term "nerolidol" refers to a compound having the following structural formula or any mixture:

OrNerolidol is generally characterized as having a woody aroma, similar to fresh bark. In the context of the present disclosure, the term "nerolidol" refers to either or both of the cis and trans isomers.

as used herein, the term "neryl acetate" refers to a compound having the following structural formula:

Neryl acetate is generally characterized as having floral and fruity notes.

As used herein, the term "nonanal" refers to a compound having the following structural formula:

nonanal is generally characterized as having a soapy, citrus odor. Nonanal is an ingredient of perfume, although it is also present in several natural oils. Nonanal (nonaldehyde) is also known as nonanal (nonanal).

as used herein, the term "nonanoic acid" refers to a carboxylic acid having the following structural formula:

Pelargonic acid is generally characterized as having an unpleasant, rancid, waxy, dirty, and cheese aroma.

As used herein, the term "octene" refers to a compound having one of the following isomeric forms:

In the context of the present disclosure, octene refers to any isomer in any single pure form or mixture in any proportion.

as used herein, the term "octanal" refers to a compound having the following structural formula:

Octanal is generally characterized by a very strong waxy, citrus, orange peel aroma.

As used herein, the term "octanoic acid" refers to a compound having the following structural formula:

octanoic acid is generally characterized as having a musty, rancid, cheese-like odor, resembling a sweat smell. Caprylic acid is used as a cosmetic surfactant and as a flavoring agent for processed cheese. Octanoic acid (octanic acid) is also known as Octanoic acid (caprylic acid).

As used herein, the term "p-cymene" refers to a compound having the following structural formula:

In the context of the present disclosure, cymene may refer to p-cymene or any other isomeric form, such as m-cymene or o-cymene.

As used herein, the term "pentyl butyrate" refers to a compound having the following structural formula:

Pentyl butyrate is generally characterized as having a reminiscent pear or apricot odor.

as used herein, the term "phellandrene" refers to either of two structural formulas:

orAlpha-phellandrene is generally characterized by a citrus, herbal, and black pepper-like odor. Beta-phellandrene is generally characterized as having a peppermint and slightly citrus odor with a slight peppermint-turpentine odor.

as used herein, the term "phenylacetaldehyde" refers to a compound having the following structural formula:

Phenylacetaldehyde is generally characterized as having a strong, pungent, honey-like sweetness and a green floral odor. Phenylacetaldehyde is present in buckwheat, chocolate and many other foods and flowers.

As used herein, the term "phenethylthiol" refers to a compound having the following formula: C8H10S, comprising a plurality of isomers.

In the context of the present disclosure, phenethylthiol refers to any isomer as a pure compound and/or any mixture. Phenethylthiols are generally characterized by a high-intensity odor of rubber.

As used herein, the term "phenylacetic acid" refers to a compound having the following structural formula:

phenylacetic acid is generally characterized as having a sour, sweet, waxy, paguma larvata, honey, rose, floral, similar to honeysuckle, with chocolate and tobacco flavors. Phenylacetic acid is also used in cosmetics for perfuming.

as used herein, the term "phytol" refers to a compound having the following structural formula:

Phytol generally has a mild floral, balsamic and green tea type aroma.

As used herein, the term "α -pinene" refers to a compound having one of the following structural formulae:

andalpha-pinene is generally characterized as having a pine-like aroma.

As used herein, the term "β -pinene" refers to a terpene having the following structural formula:

Beta-pinene is generally characterized as having a woody green pine-like odor. Beta-pinene is one of the most abundant compounds released by forest trees. Beta-pinene is an isomer of pinene.

As used herein, the term "patulin" refers to a compound having the following structural formula:

Platypodium triquetrum is generally characterized by having antiviral and antitumor properties. Palmatine is also known as celastrol methyl ester celastrol.

As used herein, the term "pulegone" refers to a compound having the following structural formula:

pulegone is generally characterized as having an odor similar to peppermint.

As used herein, the term "quercetin" refers to a compound having the following structural formula:

as used herein, the term "retinol" refers to a compound having the following structural formula:

retinol is often characterized as one type of vitamin a and can be converted to other types of vitamin a.

as used herein, the term "rutin" refers to a compound having the following structural formula:

Rutin is generally characterized as a citrus flavonoid and is found in many plants.

as used herein, the term "sabinene" refers to a compound having the following structural formula:

sabinene is generally characterized by having a pine odor of pepper, woody, herbaceous and spicy, with a citrus aroma. Sabinene is present in oak, tea tree oil, and black pepper, and is the main component of carrot seed oil. In the context of the present disclosure, the term sabinene refers to a mixture of one enantiomeric form or in any ratio.

as used herein, the term "sabinene hydrate" refers to a compound having the following structural formula:

Sabinene hydrate is generally characterized by having herbal, mint, eucalyptol, and terpyridine with pungent nuances.

as used herein, the term "cis-sabinene hydrate" refers to a compound having the following structural formula.

Cis-sabinene hydrate is generally characterized as having a balsamic odor.

As used herein, the term "trans-sabinene hydrate" refers to the following structural formula.

trans-sabinene hydrate is generally characterized as having a woody, balsamic odor.

As used herein, the term "safranal" refers to a compound having the following structural formula:

Safranal is generally characterized as the ingredient primarily responsible for saffron aroma.

As used herein, the term "α -apiene" refers to a compound having the following structural formula:

Alpha-apiene is generally characterized as having a pronounced amber odor. Alpha-apiene is one of the main components of celery seed oil.

As used herein, the term "α -citral" refers to compounds having the following structural formula:

Alpha-sinenseal is generally characterized as having a citrus orange, citrus aroma.

As used herein, the term "β -citral" refers to compounds having the following structural formula:

Beta-sinenseal is generally characterized as having a sweet, fresh, waxy and citrus odor. Beta-sinenseal is used in perfumes.

As used herein, the term "β -sitosterol" refers to a compound having the following structural formula:

Beta-sitosterol is found in pecans, avocados, pumpkin seeds, cashews, corn oil and soybeans.

as used herein, the term "squalene" refers to a compound having the following structural formula:

Squalene is generally characterized by playing an important role in the synthesis of plant and animal sterols.

As used herein, the term "taxadiene" refers to a compound having the following structural formula:

taxadienes are intermediates in the synthesis of paclitaxel.

as used herein, the term "terpine" refers to a compound having the following structural formula:

as used herein, the term "terpineol" refers to a compound having the following structural formula:

In the context of the present disclosure, terpineol includes any isomeric form, either as a single form or as a mixture in any ratio. Terpineol is widely used in the perfume industry. In the context of the present disclosure, terpineol refers to any and all isomeric forms, alpha, beta, gamma, etc.,

As used herein, the term "terpinen-4-ol" refers to an isomer of terpineol having the following structural formula:

Terpinen-4-ol is generally characterized as having an herbal, pepper, woody odor and is used in commercial perfumery. Terpinen-4-ol is believed to be the main active ingredient of tea tree oil.

As used herein, the term "α -terpinene" refers to a compound having the following structural formula:

Alpha terpinenes are generally characterized as having a lemon-citrus aroma. Alpha-terpinene is isolated from cardamom and marjoram oil.

as used herein, the term "γ -terpinene" refers to a compound having the following structural formula:

Gamma terpinene is generally characterized as having a herbaceous, citrus sweet aroma.

As used herein, the term "terpinolene" or "δ -terpinene" refers to a compound having the following structural formula:

Terpinolene is generally characterized as having an herbal aroma. The tastes of terpinolene are described as sweet, woody, lemon and lime.

As used herein, the term "thiophenol" refers to a compound having the following structural formula:

thiophenols are generally characterized as having a sulfur-containing odor.

As used herein, the term "thujone" refers to a compound having one of the following structural formulae:

OrIn the context of the present disclosure, the term "thujone" refers to any isomeric form, either in pure form or in a mixture in any proportion. Thujone is generally characterized as having a menthol-like odor.

As used herein, the term "thymol" refers to a compound having the following structural formula:

Thymol is typically present in the oil of thyme.

As used herein, the term "alpha-tocopherol" refers to a compound having the following structural formula:

alpha-tocopherol is generally characterized as having a very mild, mild vegetable oil-like odor.

As used herein, the term "coumaroundecanone" refers to a compound having the following structural formula:

The coumarone undecanones are generally characterized as having a sweet, spicy, balsamic and coumarone-like woody tobacco aroma.

as used herein, the term "undecanal" refers to an aldehyde having the following structural formula:

Undecanal is generally characterized as having a soapy, aldehydic, waxy and slightly effervescent orange citrus-flavored odor with a watermelon, pineapple and caraway background. Undecanal is a common ingredient in perfumes.

As used herein, the term "valeraldehyde" or "pentanal" refers to a compound having the following structural formula:

Valeraldehyde is generally characterized as having a fermented type, diffuse, toasted flavor, with a slightly berry-like fruity odor. Valeraldehyde is used as a flavoring agent, and has a wine-like, fermented, toasted, cocoa flavor with a chocolate flavor.

As used herein, the term "ortho-tert-butylcyclohexyl acetate" refers to a cyclic ether having the following structural formula:

Ortho-tert-butylcyclohexyl acetate is generally characterized by a mild strength earthy, fruity, green, herbaceous, saw-aged wood odor. The tert-butyl cyclohexyl acetate is used in perfume and cosmetics.

As used herein, the term "α -ylarene" refers to a compound having the following structural formula:

Alpha-ylacene is generally characterized by a pungent, fruit-like aroma. Alpha-ylacene is a natural substance commonly found in wine and is emitted by some plants.

As used herein, the term "umbelliferone" refers to a compound having the following structural formula:

As used herein, the term "vanillin" refers to a compound having the following structural formula:

Vanillin is generally characterized as having a pleasant sweet aroma and a characteristic vanilla flavor.

Disclosed herein are novel compositions comprising a unique combination of a first purified cannabinoid and a first purified terpene. In one embodiment, the first purified cannabinoid and the first purified terpene are present in a non-naturally occurring concentration. In one embodiment, the first purified cannabinoid and the first purified terpene are present in a non-naturally occurring ratio. In one embodiment, the compositions disclosed herein provide specific benefits of naturally occurring cannabinoid and/or terpene characteristics not previously available, such as those found in plants, harvested flowers, extracts, or conventional products derived therefrom.

In one embodiment, the combination of the first purified cannabinoid and the first purified terpene provides a synergistic effect on a mammalian cell receptor, such as a G protein-coupled receptor. In one embodiment, the receptor is CB 1. In one embodiment, the receptor is CB 2. In one embodiment, the receptor is GPR 55. In one embodiment, the receptor is 5 HT-1A. In one embodiment, the receptor is 5 HT-2A. In one embodiment, the receptor is TRPV 1. In one embodiment, the receptor is an opioid receptor, e.g., a μ -opioid receptor.

Disclosed herein is a composition comprising:

a first purified cannabinoid selected from THC, D9-THC, D8-THC, THCA, THCV, D8-THCV, D9-THCV, THCVA, CBD, CBDA, CBDV, CBDVA, CBC, CBCA, CBCV, CBCVA, CBG, CBGA, CBGV, CBN, CBNA, CBNV, CBNVA, CBND, CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA, CBL, CBLA, CBLV, or CBLVA; and

A first purified terpene selected from the group consisting of limonene, nerolidol, beta-myrcene, linalool, alpha-caryophyllene, beta-caryophyllene, alpha-pinene, beta-pinene, alpha-bisabolol, delta-3-carene, borneol, p-cymene, eucalyptol, alpha-humulene, alpha-terpineol, terpinolene, pulegone, camphene, and geraniol.

In the context of the present disclosure, the use of "a combination of a first purified cannabinoid and a first purified terpene" can be achieved by formulating a homogeneous mixture prior to consumption (e.g., combustion, evaporation, inhalation, or ingestion) of the mixture.

In one embodiment, the compositions disclosed herein are combined with a carrier oil.

as used herein, the term "carrier oil" refers to a substance that facilitates administration of the compositions disclosed herein. In one embodiment, the carrier oil is grape seed oil. In one embodiment, the carrier oil is coconut oil. In one embodiment, the carrier oil is polyethylene glycol.

As used herein, the term "polyethylene glycol" refers to a compound having the following structural formula:

Wherein n is an integer.

polyethylene glycols are also known as PEG, polyethylene oxide (PEO) and Polyethylene Oxide (POE).

in one embodiment, the purification components disclosed herein are purposefully selected to achieve a desired effect. In one embodiment, the purifyed component of interest is then mixed with a carrier oil. In another embodiment, the purposively purified component in the carrier oil is combined with a food product. In another embodiment, purposefully purified components in the carrier oil are combined with the beverage product. In another embodiment, purposefully purified components in the carrier oil are combined with personal care products, e.g., topical creams, soaps, shampoos, and the like. In another embodiment, the purposively purified component in the carrier oil is combined with a drug. In a further embodiment, the purposively purified component in the carrier oil is combined with a plant extract. In another embodiment, the purposively purified component in the carrier oil is used with a device, such as an evaporator, intravenous drug, or the like. In another embodiment, the purposively purified component in the carrier oil is used in combination with any of the above embodiments.

In one example, specific purification components, such as purified terpenes, can be added to purified or unpurified cannabinoids to produce the compositions disclosed herein at the time of use.

In the context of the present disclosure, the term "use" includes consumption by ingestion or heating and by, for example, combustion or evaporative inhalation.

In one example, specific purification components, such as purified terpenes, can be added to purified or unpurified cannabinoids to produce the compositions disclosed herein at the time of use. In the context of the present disclosure, the term "use" includes consumption by ingestion or heating and by, for example, combustion or evaporative inhalation.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is nerolidol.

in one embodiment, the first purified cannabinoid is THC and the first purified terpene is β -myrcene.

in one embodiment, the first purified cannabinoid is THC and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is α -pinene.

in one embodiment, the first purified cannabinoid is THC and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is THC and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is limonene.

in one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is nerolidol.

in one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is linalool.

in one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is δ -3-carene.

in one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is pulegone.

in one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is D9-THC and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is nerolidol.

in one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is β -myrcene.

in one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is β -caryophyllene.

in one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is α -bisabolol.

in one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is eucalyptol.

in one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is terpinolene.

in one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is D8-THC and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is limonene.

in one embodiment, the first purified cannabinoid is THCA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is THCA and the first purified terpene is geraniol.

in one embodiment, the first purified cannabinoid is THCV and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is α -caryophyllene.

in one embodiment, the first purified cannabinoid is THCV and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is α -bisabolol.

in one embodiment, the first purified cannabinoid is THCV and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is borneol.

in one embodiment, the first purified cannabinoid is THCV and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is pulegone.

in one embodiment, the first purified cannabinoid is THCV and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is THCV and the first purified terpene is geraniol.

in one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is limonene.

in one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is nerolidol.

in one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is α -pinene.

in one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is β -pinene.

in one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is alpha-terpineol.

in one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is terpinolene.

in one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is pulegone.

in one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is THCVA and the first purified terpene is geraniol.

in one embodiment, the first purified cannabinoid is CBD and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is linalool.

in one embodiment, the first purified cannabinoid is CBD and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is α -pinene.

in one embodiment, the first purified cannabinoid is CBD and the first purified terpene is β -pinene.

in one embodiment, the first purified cannabinoid is CBD and the first purified terpene is α -bisabolol.

in one embodiment, the first purified cannabinoid is CBD and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is a CBD and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is pulegone.

in one embodiment, the first purified cannabinoid is CBD and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBD and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is limonene.

in one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is nerolidol.

in one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is camphene.

in one embodiment, the first purified cannabinoid is CBDA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is limonene.

in one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is nerolidol.

in one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is β -myrcene.

in one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is β -caryophyllene.

in one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is β -pinene.

in one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is p-cymene.

in one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is alpha-terpineol.

in one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBDV and the first purified terpene is geraniol.

in one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is limonene.

in one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is β -myrcene.

in one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is α -caryophyllene.

in one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is β -caryophyllene.

in one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is δ -3-carene.

in one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is alpha-terpineol.

in one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBDVA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is α -pinene.

in one embodiment, the first purified cannabinoid is CBC and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is eucalyptol.

in one embodiment, the first purified cannabinoid is CBC and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is pulegone.

in one embodiment, the first purified cannabinoid is CBC and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBC and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is α -bisabolol.

in one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is borneol.

in one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is camphene.

in one embodiment, the first purified cannabinoid is CBCA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is linalool.

in one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is β -pinene.

in one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is alpha-terpineol.

in one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBCV and the first purified terpene is geraniol.

in one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is linalool.

in one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is β -caryophyllene.

in one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is p-cymene.

in one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is terpinolene.

in one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBCVA and the first purified terpene is geraniol.

in one embodiment, the first purified cannabinoid is CBG and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is p-cymene.

in one embodiment, the first purified cannabinoid is CBG and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is α -humulene.

in one embodiment, the first purified cannabinoid is CBG and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is pulegone.

in one embodiment, the first purified cannabinoid is CBG and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBG and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is β -myrcene.

in one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is linalool.

in one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBGA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is limonene.

in one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is linalool.

in one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is α -bisabolol.

in one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is δ -3-carene.

in one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is α -humulene.

in one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is terpinolene.

in one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBGV and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is limonene.

in one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is β -myrcene.

in one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is α -pinene.

in one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is borneol.

in one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is cymene.

in one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is α -humulene.

in one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBGVA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is β -pinene.

in one embodiment, the first purified cannabinoid is CBN and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is alpha-terpineol.

in one embodiment, the first purified cannabinoid is CBN and the first purified terpene is alpha-humulene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBN and the first purified terpene is geraniol.

in one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is β -pinene.

in one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is borneol.

in one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is p-cymene.

in one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBNA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is α -bisabolol.

in one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is p-cymene.

in one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is terpinolene.

in one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBNV and the first purified terpene is geraniol.

in one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is nerolidol.

in one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is β -myrcene.

in one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is linalool.

in one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is borneol.

in one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is α -piperylene.

in one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBNVA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is α -terpineol.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBND and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is linalool.

in one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is β -caryophyllene.

in one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is β -pinene.

in one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is eucalyptol.

in one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is p-cymene.

in one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is α -humulene.

in one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is terpinolene.

in one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is pulegone.

in one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBNDA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is β -myrcene.

in one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is α -caryophyllene.

in one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is borneol.

in one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is terpinolene.

in one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is pulegone.

in one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is camphene.

in one embodiment, the first purified cannabinoid is CBNDV and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is camphene.

in one embodiment, the first purified cannabinoid is CBNDVA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is β -myrcene.

in one embodiment, the first purified cannabinoid is CBL and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is α -caryophyllene.

in one embodiment, the first purified cannabinoid is CBL and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is δ -3-carene.

in one embodiment, the first purified cannabinoid is CBL and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is pulegone.

in one embodiment, the first purified cannabinoid is CBL and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBL and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is linalool.

in one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is β -pinene.

in one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is eucalyptol.

in one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is alpha-terpineol.

in one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is camphene.

in one embodiment, the first purified cannabinoid is CBLA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is β -caryophyllene.

in one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is β -pinene.

in one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is eucalyptol.

in one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is p-cymene.

in one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is α -terpineol.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is terpinolene.

in one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBLV and the first purified terpene is geraniol.

in one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is limonene.

in one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is linalool.

in one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is β -caryophyllene.

in one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is p-cymene.

in one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is α -piperylene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBLVA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is nerolidol

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is α -caryophyllene.

in one embodiment, the first purified cannabinoid is CBE and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is β -pinene.

in one embodiment, the first purified cannabinoid is CBE and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is δ -3-carene.

in one embodiment, the first purified cannabinoid is CBE and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is p-cymene.

in one embodiment, the first purified cannabinoid is CBE and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is terpinolene.

in one embodiment, the first purified cannabinoid is CBE and the first purified terpene is pulegone.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBE and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is nerolidol

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is δ -3-carene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is pulegone.

in one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is camphene.

in one embodiment, the first purified cannabinoid is CBEA and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is limonene.

in one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is nerolidol.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is β -myrcene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is β -pinene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is δ -3-carene.

in one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is borneol.

in one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is eucalyptol.

in one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is pulegone.

in one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBEV and the first purified terpene is geraniol.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is limonene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is nerolidol

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is β -myrcene.

in one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is linalool.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is α -caryophyllene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is β -caryophyllene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is α -pinene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is β -pinene.

in one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is α -bisabolol.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is delta-3-carene.

in one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is borneol.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is eucalyptol.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is p-cymene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is alpha-terpineol.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is α -humulene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is terpinolene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is pulegone.

in one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is camphene.

In one embodiment, the first purified cannabinoid is CBEVA and the first purified terpene is geraniol.

In one embodiment of the composition disclosed herein, the first purified cannabinoid and the first purified terpene comprise 80-100% of the total mass of the composition.

in one embodiment of the composition disclosed herein, the first purified cannabinoid and the first purified terpene comprise from 85% to 100% of the total mass of the composition.

In one embodiment of the composition disclosed herein, the first purified cannabinoid and the first purified terpene comprise 90-100% of the total mass of the composition.

in one embodiment of the composition disclosed herein, the first purified cannabinoid and the first purified terpene comprise 95-100% of the total mass of the composition.

In one embodiment of the composition disclosed herein, the first purified cannabinoid and the first purified terpene comprise 99-100% of the total mass of the composition.

In one embodiment of the disclosed compositions, the ratio of first purified cannabinoid to first purified terpene is greater than 100: 1, for example at 100: 1 and 500: 1.

In one embodiment of the disclosed composition, the ratio of first purified cannabinoid to first purified terpene is 100: 1 to 10: 1.

In one embodiment of the disclosed composition, the ratio of purified cannabinoid to purified terpene is 20: 1 to 10: 1.

In one embodiment of the disclosed composition, the ratio of purified cannabinoid to purified terpene is 10:1 to 1: 1.

in one embodiment of the disclosed composition, the ratio of purified cannabinoid to purified terpene is 5: 1 to 1: 1.

In one embodiment of the disclosed composition, the ratio of purified cannabinoid to purified terpene is 3: 1 to 1: 1.

In one embodiment of the disclosed composition, the ratio of purified cannabinoid to purified terpene is from 1:1 to 1: 10.

In one embodiment of the disclosed composition, the ratio of purified cannabinoid to purified terpene is from 1:10 to 1: 100.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified β -pinene of 300: 1 to 5: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified β -pinene of 250: 1 to 10: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified β -pinene of 200: 1 to 15: 1.

in one embodiment, the composition disclosed herein comprises a ratio of THC to purified β -pinene of 150: 1 to 30: 1.

in one embodiment, the composition disclosed herein comprises THC in a ratio to purified β -pinene of 100: 1 to 35: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified β -pinene of 75: 1 to 40: 1.

In one embodiment, the compositions disclosed herein comprise a purified β -pinene to CBG ratio of greater than 2: 1.

In one embodiment, the composition disclosed herein comprises a purified β -pinene to CBG ratio of 2: 1 to 4: 1.

In one embodiment, the composition disclosed herein comprises a purified β -pinene to CBG ratio of 4: 1 to 16: 1.

in one embodiment, the composition disclosed herein comprises a purified β -pinene to CBG ratio of 16: 1 to 32: 1.

In one embodiment, the composition disclosed herein comprises a purified β -pinene to CBG ratio of 32: 1 and 64: 1.

In one embodiment, the compositions disclosed herein comprise a purified β -pinene to CBG ratio of greater than 100: 1.

in one embodiment, the composition disclosed herein comprises THC in a ratio of 950: 1 to 25: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of THC to purified eucalyptol of 875: 1 to 35: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified eucalyptol of 750: 1 to 45: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified eucalyptol of 625: 1 to 55: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified eucalyptol of 500: 1 to 65: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified eucalyptol of 350: 1 to 75: 1.

in one embodiment, the composition disclosed herein comprises THC in a ratio to purified eucalyptol of 240: 1 to 100: 1.

In one embodiment, the compositions disclosed herein comprise purified eucalyptol to CBG in a ratio of greater than 0.625: 1.

In one embodiment, the compositions disclosed herein comprise purified eucalyptol to CBG in a ratio of 0.625: 1 to 5: 1.

In one embodiment, the compositions disclosed herein comprise purified eucalyptol and CBG in a ratio of 5: 1 to 25: 1.

In one embodiment, the compositions disclosed herein comprise purified eucalyptol and CBG in a ratio of 25: 1 to 50: 1.

in one embodiment, the composition disclosed herein comprises purified eucalyptol and CBG in a ratio of 50: 1 to 75: 1.

in one embodiment, the composition disclosed herein comprises purified eucalyptol and CBG in a ratio of 75: 1 to 100: 1.

in one embodiment, the compositions disclosed herein comprise purified eucalyptol to CBG in a ratio of greater than 100: 1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-humulene in a ratio of 400: 1 to 10: 1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-humulene in a ratio of 350: 1 to 20: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of THC to purified alpha-humulene of 300: 1 to 25: 1.

in one embodiment, the compositions disclosed herein comprise a ratio of THC to purified alpha-humulene of 250: 1 to 30: 1.

in one embodiment, the compositions disclosed herein comprise THC to purified alpha-humulene in a ratio of 200: 1 to 35: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of THC to purified alpha-humulene of 150: 1 to 40: 1.

In one embodiment, the compositions disclosed herein comprise THC to purified alpha-humulene in a ratio of 100: 1 to 50: 1.

in one embodiment, the compositions disclosed herein comprise purified alpha-humulene to CBG ratios of greater than 1.5: 1.

In one embodiment, the compositions disclosed herein comprise purified alpha-humulene to CBG in a ratio of 1.5: 1 to 3: 1.

In one embodiment, the compositions disclosed herein comprise purified alpha-humulene to CBG in a ratio of 3: 1 to 9: 1.

In one embodiment, the compositions disclosed herein comprise purified alpha-humulene to CBG in a ratio of 9: 1 to 27: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified alpha-humulene to CBG of 27: 1 to 81: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified alpha-humulene to CBG of greater than 100: 1.

in one embodiment, the composition disclosed herein comprises THC in a ratio to purified linalool of 950: 1 to 25: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of THC to purified linalool of 875: 1 to 35: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified linalool of 750: 1 to 45: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified linalool of 625: 1 to 55: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified linalool of 500: 1 to 65: 1.

in one embodiment, the composition disclosed herein comprises THC in a ratio to purified linalool of 350: 1 to 75: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified linalool of 240: 1 to 100: 1.

in one embodiment, the compositions disclosed herein comprise a ratio of purified linalool to CBG of greater than 0.625: 1.

In one embodiment, the composition disclosed herein comprises purified linalool at a ratio of 0.625: 1 to 5: 1.

in one embodiment, the composition disclosed herein comprises purified linalool at a ratio of 5: 1 to 25: 1.

in one embodiment, the composition disclosed herein comprises purified linalool at a ratio of 25: 1 to 50: 1.

In one embodiment, the composition disclosed herein comprises purified linalool at a ratio of 50: 1 to 75: 1.

In one embodiment, the composition disclosed herein comprises purified linalool in a ratio of 75: 1 to 100: 1.

In one embodiment, the composition disclosed herein comprises a ratio of purified linalool to CBG of greater than 100: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified limonene of 350: 1 to 10: 1.

in one embodiment, the composition disclosed herein comprises a ratio of THC to purified limonene of 300: 1 to 15: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified limonene of 250: 1 to 20: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified limonene of 200: 1 to 25: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified limonene of 150: 1 to 30: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified limonene of 100: 1 to 35: 1.

in one embodiment, the composition disclosed herein comprises a ratio of THC to purified limonene of 85: 1 to 40: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified limonene to CBG of greater than 3.5: 1.

In one embodiment, the composition disclosed herein comprises a ratio of purified limonene to CBG of 3.5: 1 to 7: 1.

In one embodiment, the composition disclosed herein comprises a ratio of purified limonene to CBG of 7: 1 to 25: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified limonene to CBG in the range of 25: 1 and 50: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified limonene to CBG in the range of 50: 1 and 75: 1.

In one embodiment, the composition disclosed herein comprises a ratio of purified limonene to CBG in the range of 75: 1 and 100: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified limonene to CBG of greater than 100: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified nerolidol of 150: 1 to 4: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified nerolidol of 120: 1 to 10: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified nerolidol of 60: 1 to 15: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified nerolidol of 30: 1 to 20: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified nerolidol to CBG of greater than 3: 1.

In one embodiment, the composition disclosed herein comprises a ratio of purified nerolidol to CBG of 3: 1 to 10: 1.

In one embodiment, the composition disclosed herein comprises a ratio of purified nerolidol to CBG of 10:1 to 25: 1.

in one embodiment, the compositions disclosed herein comprise a ratio of purified nerolidol to CBG of between 25: 1 and 50: 1.

In one embodiment, the composition disclosed herein comprises a ratio of purified nerolidol to CBG between 50: 1 and 75: 1.

In one embodiment, the composition disclosed herein comprises a ratio of purified nerolidol to CBG of between 75: 1 and 100: 1.

in one embodiment, the composition disclosed herein comprises a ratio of purified nerolidol to CBG of greater than 100: 1.

in one embodiment, the compositions disclosed herein comprise THC in a ratio to purified β -caryophyllene of 150: 1 to 4: 1.

in one embodiment, the compositions disclosed herein comprise THC in a ratio to purified β -caryophyllene of 120: 1 to 5: 1.

In one embodiment, the compositions disclosed herein comprise THC in a ratio to purified β -caryophyllene of 60: 1 to 15: 1.

In one embodiment, the compositions disclosed herein comprise THC in a ratio to purified β -caryophyllene of 30: 1 to 20: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified β -caryophyllene to CBG of greater than 3: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified β -caryophyllene to CBG of 3: 1 to 10: 1.

In one embodiment, the compositions disclosed herein comprise a purified β -caryophyllene to CBG ratio of 10:1 to 25: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified β -caryophyllene to CBG in the range of 25: 1 and 50: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified β -caryophyllene to CBG in the range of 50: 1 and 75: 1.

in one embodiment, the compositions disclosed herein comprise a ratio of purified β -caryophyllene to CBG in the range of 75: 1 and 100: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified β -caryophyllene to CBG of greater than 100: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified alpha-pinene of 300: 1 to 5: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified alpha-pinene of 250: 1 to 10: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified alpha-pinene of 200: 1 to 15: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified alpha-pinene of 150: 1 to 30: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified alpha-pinene of 100: 1 to 35: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified alpha-pinene of 75: 1 to 40: 1.

In one embodiment, the compositions disclosed herein comprise a purified alpha-pinene to CBG ratio of greater than 2: 1.

In one embodiment, the composition disclosed herein comprises a purified alpha-pinene to CBG ratio of 2: 1 to 4: 1.

in one embodiment, the composition disclosed herein comprises a purified alpha-pinene to CBG ratio of 4: 1 to 16: 1.

In one embodiment, the composition disclosed herein comprises a purified alpha-pinene to CBG ratio of 16: 1 to 32: 1.

in one embodiment, the composition disclosed herein comprises a purified alpha-pinene to CBG ratio of 32: 1 and 64: 1.

In one embodiment, the compositions disclosed herein comprise a purified alpha-pinene to CBG ratio of greater than 100: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified beta-myrcene of 200: 1 to 3: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio of 175: 1 to 7.5: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified beta-myrcene of 150: 1 to 10: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified beta-myrcene of 125: 1 to 12.5: 1.

in one embodiment, the composition disclosed herein comprises THC in a ratio to purified beta-myrcene of 100: 1 to 15: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified beta-myrcene of 75: 1 to 17.5: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified beta-myrcene of 50: 1 to 20: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified beta-myrcene to CBG greater than 3: 1.

in one embodiment, the compositions disclosed herein comprise purified beta-myrcene in a ratio of 3: 1 to 10: 1.

In one embodiment, the compositions disclosed herein comprise purified beta-myrcene in a ratio to CBG of 10:1 to 25: 1.

In one embodiment, the compositions disclosed herein comprise purified beta-myrcene in a ratio of 25: 1 to 50: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified beta-myrcene to CBG in the range of 50: 1 and 75: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified beta-myrcene to CBG in the range of 75: 1 and 100: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified beta-myrcene to CBG of greater than 100: 1.

in one embodiment, the compositions disclosed herein comprise THC in a ratio to purified alpha terpineol of 2,000: 1 to 50: 1.

In one embodiment, the compositions disclosed herein comprise THC in a ratio to purified alpha terpineol of 1,750: 1 to 75: 1.

In one embodiment, the compositions disclosed herein comprise THC in a ratio to purified alpha terpineol of 1,500: 1 to 100: 1.

in one embodiment, the compositions disclosed herein comprise THC in a ratio of 1250: 1 to 125: 1.

In one embodiment, the compositions disclosed herein comprise THC in a ratio to purified alpha terpineol of 1,000: 1 to 150: 1.

In one embodiment, the compositions disclosed herein comprise THC in a ratio to purified alpha terpineol of 750: 1 to 175: 1.

In one embodiment, the compositions disclosed herein comprise THC in a ratio to purified alpha terpineol of 500: 1 to 200: 1.

in one embodiment, the compositions disclosed herein comprise a ratio of purified alpha-terpineol to CBG of greater than 0.3: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified alpha-terpineol to CBG of 0.3: 1 to 1: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified alpha-terpineol to CBG of 0.3: 1 to 5: 1.

In one embodiment, the compositions disclosed herein comprise purified alpha-terpineol to CBG in a ratio of 5: 1 to 25: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified alpha-terpineol to CBG of 25: 1 to 50: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified alpha-terpineol to CBG of between 50: 1 and 75: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified alpha-terpineol to CBG of 75: 1 to 100: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified alpha-terpineol to CBG of greater than 100: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified terpinolene of 1,200: 1 to 30: 1.

in one embodiment, the composition disclosed herein comprises THC in a ratio to purified terpinolene of 1,000: 1 to 45: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified terpinolene of 900: 1 to 60: 1.

in one embodiment, the composition disclosed herein comprises THC in a ratio to purified terpinolene of 750: 1 to 75: 1.

in one embodiment, the composition disclosed herein comprises THC in a ratio to purified terpinolene of 600: 1 to 90: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified terpinolene of 425: 1 to 105: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified terpinolene of 350: 1 to 120: 1.

in one embodiment, the composition disclosed herein comprises a ratio of purified terpinolene to CBG of more than 0.5: 1.

In one embodiment, the composition disclosed herein comprises a ratio of purified terpinolene to CBG of 0.5: 1 to 1: 1.

In one embodiment, the composition disclosed herein comprises purified terpinolene in a ratio to CBG of 1:1 to 5: 1.

In one embodiment, the composition disclosed herein comprises purified terpinolene in a ratio to CBG of 5: 1 to 25: 1.

In one embodiment, the composition disclosed herein comprises purified terpinolene in a ratio to CBG of 25: 1 to 50: 1.

In one embodiment, the composition disclosed herein comprises purified terpinolene in a ratio to CBG of 50: 1 to 75: 1.

In one embodiment, the composition disclosed herein comprises a ratio of purified terpinolene to CBG of 75: 1 to 100: 1.

In one embodiment, the composition disclosed herein comprises a ratio of purified terpinolene to CBG of more than 100: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified pulegone of 1,200: 1 to 30: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified pulegone of 1,000: 1 to 45: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified pulegone of 900: 1 to 60: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified pulegone of 750: 1 to 75: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified pulegone of 600: 1 to 90: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified pulegone of 425: 1 to 105: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified pulegone of 350: 1 to 120: 1.

in one embodiment, the compositions disclosed herein comprise a ratio of purified pulegone to CBG of greater than 0.5: 1.

In one embodiment, the composition disclosed herein comprises purified pulegone in a ratio to CBG of 0.5: 1 to 1: 1.

in one embodiment, the composition disclosed herein comprises purified pulegone in a ratio to CBG of 1:1 to 5: 1.

In one embodiment, the composition disclosed herein comprises purified pulegone in a ratio to CBG of 5: 1 to 25: 1.

in one embodiment, the composition disclosed herein comprises purified pulegone in a ratio to CBG of 25: 1 to 50: 1.

In one embodiment, the composition disclosed herein comprises purified pulegone in a ratio to CBG of 50: 1 to 75: 1.

In one embodiment, the composition disclosed herein comprises purified pulegone in a ratio to CBG of 75: 1 to 100: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified pulegone to CBG of greater than 100: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified camphene of 950: 1 to 25: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified camphene of 875: 1 to 35: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified camphene of 750: 1 to 45: 1.

in one embodiment, the composition disclosed herein comprises THC in a ratio to purified camphene of 625: 1 to 55: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified camphene of 500: 1 to 65: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified camphene of 350: 1 to 75: 1.

in one embodiment, the composition disclosed herein comprises a ratio of THC to purified camphene of 240: 1 to 100: 1.

in one embodiment, the composition disclosed herein comprises a purified camphene to CBG ratio of greater than 0.625: 1.

in one embodiment, the composition disclosed herein comprises a purified camphene to CBG ratio of 0.625: 1 to 5: 1.

In one embodiment, the composition disclosed herein comprises purified camphene and CBG in a ratio of 5: 1 to 25: 1.

In one embodiment, the composition disclosed herein comprises a purified camphene to CBG ratio of 25: 1 to 50: 1.

in one embodiment, the composition disclosed herein comprises a ratio of purified camphene to CBG between 50: 1 and 75: 1.

In one embodiment, the composition disclosed herein comprises a ratio of purified camphene to CBG of between 75: 1 and 100: 1.

In one embodiment, the composition disclosed herein comprises a purified camphene to CBG ratio of greater than 100: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified delta-3-carene of 950: 1 to 25: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified delta-3-carene of 875: 1 to 35: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified delta-3-carene of 750: 1 to 45: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified delta-3-carene of 625: 1 to 55: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified delta-3-carene of 500: 1 to 65: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified delta-3-carene of 350: 1 to 75: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified delta-3-carene of 240: 1 to 100: 1.

In one embodiment, the composition disclosed herein comprises a ratio of purified delta-3-carene to CBG of greater than 0.625: 1.

In one embodiment, the composition disclosed herein comprises a ratio of purified delta-3-carene to CBG of 0.625: 1 to 5: 1.

In one embodiment, the composition disclosed herein comprises a ratio of purified delta-3-carene to CBG of 5: 1 to 25: 1.

in one embodiment, the composition disclosed herein comprises a ratio of purified delta-3-carene to CBG of 25: 1 to 50: 1.

in one embodiment, the composition disclosed herein comprises a ratio of purified delta-3-carene to CBG between 50: 1 and 75: 1.

In one embodiment, the composition disclosed herein comprises a ratio of purified delta-3-carene to CBG of 75: 1 to 100: 1.

In one embodiment, the composition disclosed herein comprises a ratio of purified delta-3-carene to CBG of greater than 100: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified geraniol of 950: 1 to 25: 1.

in one embodiment, the compositions disclosed herein comprise a ratio of THC to purified geraniol of 875: 1 to 35: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of THC to purified geraniol of 750: 1 to 45: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified geraniol of 625: 1 to 55: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified geraniol of 500: 1 to 65: 1.

In one embodiment, the composition disclosed herein comprises a ratio of THC to purified geraniol of 350: 1 to 75: 1.

in one embodiment, the composition disclosed herein comprises a ratio of THC to purified geraniol of 240: 1 to 100: 1.

in one embodiment, the compositions disclosed herein comprise a ratio of purified geraniol to CBG of greater than 0.625: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified geraniol to CBG of 0.625: 1 to 5: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified geraniol to CBG in the range of 5: 1 and 25: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified geraniol to CBG of 25: 1 to 50: 1.

in one embodiment, the compositions disclosed herein comprise a ratio of purified geraniol to CBG between 50: 1 and 75: 1.

in one embodiment, the compositions disclosed herein comprise a ratio of purified geraniol to CBG between 75: 1 and 100: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified geraniol to CBG of greater than 100: 1.

in one embodiment, the composition disclosed herein comprises THC in a ratio of 950: 1 to 25: 1.

in one embodiment, the compositions disclosed herein comprise a ratio of THC to purified p-cymene of 875: 1 to 35: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified p-cymene of 750: 1 to 45: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified p-cymene of 625: 1 to 55: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified p-cymene of 500: 1 to 65: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified p-cymene of 350: 1 to 75: 1.

In one embodiment, the composition disclosed herein comprises THC in a ratio to purified p-cymene of 240: 1 to 100: 1.

in one embodiment, the compositions disclosed herein comprise a purified p-cymene to CBG ratio of greater than 0.625: 1.

in one embodiment, the compositions disclosed herein comprise purified p-cymene to CBG in a ratio of 0.625: 1 to 5: 1.

In one embodiment, the compositions disclosed herein comprise purified p-cymene and CBG in a ratio of 5: 1 to 25: 1.

In one embodiment, the compositions disclosed herein comprise purified p-cymene and CBG in a ratio of 25: 1 and 50: 1.

In one embodiment, the compositions disclosed herein comprise purified p-cymene and CBG in a ratio of 50: 1 and 75: 1.

in one embodiment, the compositions disclosed herein comprise purified p-cymene and CBG in a ratio of 75: 1 and 100: 1.

In one embodiment, the compositions disclosed herein comprise a ratio of purified p-cymene to CBG of greater than 100: 1.

In one embodiment, the combination of the first purified cannabinoid and the first purified terpene comprises a second purified cannabinoid selected from THC, D9-THC, D8-THC, THCA, THCV, D8-THCV, D9-THCV, THCVA, CBD, CBDA, CBDV, CBDVA, CBC, CBCA, CBCV, CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND, CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA, CBL, CBLA, CBLV, or CBLVA.

thus, disclosed herein are novel compositions comprising a unique combination of a first purified cannabinoid, a second purified cannabinoid, and a first purified terpene. In one embodiment, the compositions disclosed herein comprise a first purified cannabinoid, a second purified cannabinoid, and a first purified terpene present in a non-naturally occurring concentration. In one embodiment, the compositions disclosed herein comprise a first purified cannabinoid, a second purified cannabinoid, and a first purified terpene present in a non-naturally occurring ratio. In one embodiment, the compositions disclosed herein provide specific benefits of naturally occurring cannabinoid characteristics not previously available, such as those found in plants, harvested flowers, extracts, or conventional products derived therefrom.

In one embodiment of the disclosed compositions, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is greater than 100: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is 100: 1:1 to 10: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is 20: 1:1 to 10: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is 10: 1:1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is 5: 1:1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is 3: 1:1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is from 1: 1:1 to 1: 1: 10.

in one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is from 1: 1:10 to 1: 1: 100.

in one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is 100: 50: 1 to 10: 5: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is 50: 10:1 to 5: 2: 1.

in one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is from 25: 15: 1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is from 1: 1:1 to 1: 5: 5.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is from 1: 5: 5 to 1: 25: 100.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is 100: 100: 1 to 10: 10: 1.

in one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is 20: 20: 1 to 10: 10: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is 10: 10:1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is 5: 5: 1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is 3: 3: 1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is from 1: 1:1 to 1:10: 10.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to first purified terpene is from 1:10:10 to 1: 100: 100.

In one embodiment of the disclosed composition, the first purified cannabinoid, the second purified cannabinoid, and the first purified terpene together comprise 80-100% by weight of the total composition.

In one embodiment of the disclosed composition, the first purified cannabinoid, the second purified cannabinoid, and the first purified terpene together comprise from 85% to 100% by weight of the total composition.

In one embodiment of the disclosed composition, the first purified cannabinoid, the second purified cannabinoid, and the first purified terpene together comprise 90-100% by weight of the total composition.

In one embodiment of the disclosed composition, the first purified cannabinoid, the second purified cannabinoid, and the first purified terpene together comprise 95-100% by weight of the total composition.

In one embodiment of the disclosed composition, the first purified cannabinoid, the second purified cannabinoid, and the first purified terpene together comprise 99-100% by weight of the total composition.

in one embodiment, the combination of the first purified cannabinoid and the first purified terpene described above comprises a second purified terpene selected from the group consisting of limonene, nerolidol, β -myrcene, linalool, α -caryophyllene, β -caryophyllene, α -pinene, β -pinene, α -bisabolol, δ -3-carene, borneol, p-cymene, eucalyptol, α -humulene, α -terpineol, terpinolene, pulegone, camphene, and geraniol.

Thus, disclosed herein are novel compositions comprising a unique combination of a first purified cannabinoid, the first purified terpene, and a second purified terpene present in concentrations that are not naturally occurring. In one embodiment, the first purified cannabinoid, the first purified terpene, and the second purified terpene are present in a non-naturally occurring ratio. In one embodiment, the compositions disclosed herein provide specific benefits of naturally occurring cannabinoid profiles not previously available, such as those found in plants, harvested flowers, extracts, or conventional products derived therefrom.

In one embodiment of the disclosed composition, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is greater than 100: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is 100: 1:1 to 10: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is 20: 1:1 to 10: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is 10: 1:1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is 5: 1:1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is 3: 1:1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 1: 1:1 to 1: 1: 10.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 1: 1:10 to 1: 1: 100.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is 100: 50: 1 to 10: 5: 1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is 50: 10:1 to 5: 2: 1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 25: 15: 1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 1: 1:1 to 1: 5: 5.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 1: 5: 5 to 1: 25: 100.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is 100: 100: 1 to 10: 10: 1.

in one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is 20: 20: 1 to 10: 10: 1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is 10: 10:1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is 5: 5: 1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is 3: 3: 1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 1: 1:1 to 1:10: 10.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene is from 1:10:10 to 1: 100: 100.

In one embodiment of the disclosed composition, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene together comprise 80-100% of the total mass of the composition.

In one embodiment of the disclosed composition, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene together comprise 85-100% of the total mass of the composition.

In one embodiment of the disclosed composition, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene together comprise 90-100% of the total mass of the composition.

In one embodiment of the disclosed composition, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene together comprise 95-100% of the total mass of the composition.

In one embodiment of the disclosed composition, the ratio of the first purified cannabinoid to the first purified terpene to the second purified terpene together comprise 99-100% of the total mass of the composition.

disclosed herein are novel compositions comprising a combination of a first purified cannabinoid and a second purified cannabinoid. In one embodiment, the compositions disclosed herein are artificial. In one embodiment, the first purified cannabinoid and the second purified cannabinoid are present in a concentration that is not naturally occurring. In one embodiment, the first purified cannabinoid and the second purified cannabinoid are present in a non-naturally occurring ratio. In one embodiment, the compositions disclosed herein provide specific benefits of naturally occurring cannabinoid profiles not previously available, such as those found in plants, harvested flowers, extracts, or conventional products derived therefrom.

in one embodiment, the combination of the first purified cannabinoid and the second purified cannabinoid provides a synergistic effect on a mammalian cell receptor, such as a G protein-coupled receptor. In one embodiment, the receptor is CB 1. In one embodiment, the receptor is CB 2. In one embodiment, the receptor is GPR 55. In one embodiment, the receptor is 5 HT-1A. In one embodiment, the receptor is 5 HT-2A. In one embodiment, the receptor is TRPV 1. In one embodiment, the receptor is an opioid receptor, e.g., a μ -opioid receptor.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid is greater than 100: 1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid is in the range of 100: 1 to 10: 1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid is 20: 1 to 10: 1.

in one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid is 10:1 to 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid is 5: 1 to 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid is 3: 1 to 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of the first purified cannabinoid to the second purified cannabinoid is from 1:1 to 1: 10.

in one embodiment of the composition disclosed herein, the first purified cannabinoid and the second purified cannabinoid are present in an amount of 80% to 100% by weight of the total composition.

In one embodiment of the composition disclosed herein, the first purified cannabinoid and the second purified cannabinoid are present in an amount of 85 to 100% by weight of the total composition.

In one embodiment of the composition disclosed herein, the first purified cannabinoid and the second purified cannabinoid are present in an amount of 90% to 100% by weight of the total composition.

In one embodiment of the composition disclosed herein, the first purified cannabinoid and the second purified cannabinoid are present in an amount of 95-100% by weight of the total composition.

In one embodiment of the composition disclosed herein, the first purified cannabinoid and the second purified cannabinoid are present in an amount of 99 to 100% by weight of the total composition.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is D8-THC.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is THCA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is THCV.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is THCVA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBD.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBDA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBDV.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBDVA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBC.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBCA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBCV.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBCVA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBG.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBGA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBGV.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBGVA.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBN.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBNA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBNV.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D9-THC and the second purified cannabinoid is CBNVA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is THCA.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is THCV.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is THCVA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBD.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBDA.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBDV.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBDVA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBC.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBCA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBCV.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBCVA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBG.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBGA.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBGV.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBGVA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBN.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBNA.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBNV.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is D8-THC and the second purified cannabinoid is CBNVA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is THCV.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is THCVA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBD.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBDA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBDV.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBDVA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBC.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBCA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBCV.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBCVA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBG.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBGA.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBGV.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBGVA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBN.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBNA.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBNV.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCA and the second purified cannabinoid is CBNVA.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is THCVA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBD.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBDA.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBDV.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBDVA.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBC.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBCA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBCV.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBCVA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBG.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBGV.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBGVA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBN.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBNV.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is THCV and the second purified cannabinoid is CBNVA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBD.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBDA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBDV.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBDVA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBC.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBCA.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBCV.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBCVA.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBG.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBGV.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBGVA.

in one embodiment of the composition disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBN.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBNV.

In one embodiment of the composition disclosed herein, the first purified cannabinoid is THCVA and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBDA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBDV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBDVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBC.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBCA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBG.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBGVA.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBN.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBD and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBDV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBDVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBC.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBCA.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBCVA.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBG.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBGVA.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBNA.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDA and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBDVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBC.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBCA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBG.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBGA.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDV and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBC.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBCA.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBG.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBGV.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBGVA.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBDVA and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBCA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBCVA.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBG.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBC and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBCV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBG.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBGA.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBGVA.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBN.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBNA.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCA and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBCVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBG.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBNV.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCV and the second purified cannabinoid is CBCA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCVA and the second purified cannabinoid is CBG.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCVA and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCVA and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCVA and the second purified cannabinoid is CBGVA.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCVA and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCVA and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCVA and the second purified cannabinoid is CBNV.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBCVA and the second purified cannabinoid is CBNVA.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBG and the second purified cannabinoid is CBGA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBG and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBG and the second purified cannabinoid is CBGVA.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBG and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBG and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBG and the second purified cannabinoid is CBNV.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBG and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGA and the second purified cannabinoid is CBGV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGA and the second purified cannabinoid is CBGVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGA and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGA and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGA and the second purified cannabinoid is CBNV.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGA and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGV and the second purified cannabinoid is CBN.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGV and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGV and the second purified cannabinoid is CBNV.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGV and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGVA and the second purified cannabinoid is CBN.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGVA and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGVA and the second purified cannabinoid is CBNV.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBGVA and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBN and the second purified cannabinoid is CBNA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBN and the second purified cannabinoid is CBNV.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBN and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBNA and the second purified cannabinoid is CBNV.

in one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBNA and the second purified cannabinoid is CBNVA.

In one embodiment of the compositions disclosed herein, the first purified cannabinoid is CBNV, and the second purified cannabinoid is CBNVA.

In one embodiment, the combination of first purified cannabinoid and second purified cannabinoid described above comprises a third purified cannabinoid selected from THC, D9-THC, D8-THC, THCA, THCV, D8-THCV, D9-THCV, THCVA, CBD, CBDA, CBDV, CBDVA, CBC, CBCA, CBCV, CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND, CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA, CBL, CBLA, CBLV, or CBLVA.

Thus, disclosed herein are novel compositions comprising a unique combination of a first purified cannabinoid, a second purified cannabinoid, and a third purified cannabinoid. In one embodiment, the compositions disclosed herein comprise a first purified cannabinoid, a second purified cannabinoid, and a third purified cannabinoid, present in a concentration that is not naturally occurring. In one embodiment, the compositions disclosed herein comprise a first purified cannabinoid, a second purified cannabinoid, and a third purified cannabinoid, present in a non-naturally occurring ratio. In one embodiment, the compositions disclosed herein provide specific benefits of naturally occurring cannabinoid profiles not previously available, such as those found in plants, harvested flowers, extracts, or conventional products derived therefrom.

in one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is greater than 100: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is in the range of 100: 1:1 to 10: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is 20: 1:1 to 10: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is 10: 1:1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is 5: 1:1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is 3: 1:1 to 1: 1: 1.

in one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is from 1: 1:1 to 1: 1: 10.

in one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is from 1: 1:10 to 1: 1: 100.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is in the range of 100: 50: 1 to 10: 5: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is 50: 10:1 to 5: 2: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is from 25: 15: 1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is from 1: 1:1 to 1: 5: 5.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is from 1: 5: 5 to 1: 25: 100.

in one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is 100: 100: 1 to 10: 10: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is 20: 20: 1 to 10: 10: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is 10: 10:1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is 5: 5: 1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is 3: 3: 1 to 1: 1: 1.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is from 1: 1:1 to 1:10: 10.

In one embodiment of the compositions disclosed herein, the ratio of first purified cannabinoid to second purified cannabinoid to third purified cannabinoid is from 1:10:10 to 1: 100: 100.

Examples

the following examples are provided as non-limiting illustrations of the broader disclosure.

Example 1:

A composition was formulated by combining the following components: purified THC (99g) and purified β -pinene (0.8 g).

Example 2:

a composition was formulated by combining the following components: purified THC (99g) and purified geraniol (0.5 g).

Example 3:

A composition was formulated by combining the following components: purified THC (99g) and purified p-cymene (0.5 g).

Example 4:

a composition was formulated by combining the following components: purified THC (99g) and purified delta-3-carene (0.25 g).

example 5:

A composition was formulated by combining the following components: purified THC (99g) and purified camphene (0.375 g).

Example 6:

a composition was formulated by combining the following components: purified THC (99g) and purified pulegone (0.3 g).

Example 7:

A composition was formulated by combining the following components: purified THC (99g) and purified terpinolene (0.3 g).

Example 8:

A composition was formulated by combining the following components: purified THC (99g) and purified alpha-terpineol (0.2 g).

Example 9:

A composition was formulated by combining the following components: purified THC (98g) and purified beta-myrcene (1.25 g).

Example 10:

A composition was formulated by combining the following components: purified THC (99g) and purified alpha-pinene (0.8 g).

Example 11:

A composition was formulated by combining the following components: purified THC (98g) and purified beta-caryophyllene (1.5 g).

Example 12:

A composition was formulated by combining the following components: purified THC (98g) and purified nerolidol (1.5 g).

Example 13:

A composition was formulated by combining the following components: purified THC (97g) and purified limonene (1.4 g).

Example 14:

a composition was formulated by combining the following components: purified THC (99g) and purified linalool (0.375 g).

Example 15:

a composition was formulated by combining the following components: purified THC (99g) and purified β -pinene (0.8 g).

Example 16:

A composition was formulated by combining the following components: purified THC (99g) and purified eucalyptol (0.5 g).

Example 17:

A composition was formulated by combining the following components: purified THC (99g) and purified alpha-humulene (0.9 g).

Example 18:

A composition was formulated by combining the following components: purified THC (51g), purified CBD (10g), purified CBG (4g), purified linalool (0.5g), purified limonene (0.5g) and purified alpha-humulene (0.5 g).

Example 19:

A composition was formulated by combining the following components: purified THC (50g), purified THCV (10g), purified CBG (4g), purified CBC (0.2g), purified beta-pinene (2g), purified beta-caryophyllene (0.5g), purified limonene (1g) and purified eucalyptol (0.25 g).

Example 20:

A composition was formulated by combining the following components: purified THC (20 g); purified CBC (10 g); purified CBN (0.2 g); purified THCV (0.6 g); and purified β -pinene (0.8 g).

Example 21:

A composition was formulated by combining the following components: purified THC (51 g); purified CBD (0.2 g); purified CBC (0.2 g); purified CBN (0.2 g); purified THCV (0.6 g); purified beta-caryophyllene (1.6 g); and purified alpha-terpineol (0.16 g).

Example 22:

A composition was formulated by combining the following components: purified THC (51g), purified β -pinene (1g), purified α -terpineol (0.1g) and purified linalool (0.1 g).

Example 23:

a composition was formulated by combining the following components: purified THC (51g), purified β -pinene (1g), purified α -terpineol (0.1g), purified linalool (0.1g) and polyethylene glycol (25 g).

Example 24:

A composition was formulated by combining the following components: purified THC (51 g); purified CBD (0.2 g); purified CBC (0.2 g); purified CBN (0.2 g); purified THCV (0.6 g); purified beta-caryophyllene (1 g); and purified linalool (0.1 g).

example 25:

a composition was formulated by combining the following components: purified THC (51g), purified alpha-pinene (1.6g) and purified linalool (0.25 g).

Example 26:

A composition was formulated by combining the following components: purified THC (51g), purified alpha-pinene (1.6g), purified linalool (0.25g) and purified alpha-humulene (0.6 g).

Example 27:

The following components were combined to prepare a composition: purified THC (51g), purified linalool (0.5g), purified alpha-pinene (0.75g) and purified eucalyptol (0.75 g).

Example 28:

The following components were combined to prepare a composition: purified THC (51g), purified linalool (0.5g), purified alpha-pinene (0.75g), purified eucalyptol (0.75g) and purified nerolidol (1.5 g).

Example 29:

The following components were combined to prepare a composition: purified THC (51g), purified linalool (0.5g), purified alpha-pinene (1.6g), purified eucalyptol (0.75g) and polyethylene glycol (25 g).

Example 30:

the following components were combined to prepare a composition: purified THC (51g), purified linalool (0.5g), purified alpha-pinene (1.6g), purified eucalyptol (0.75g), purified terpinolene (0.25g) and polyethylene glycol (25 g).

Example 31:

The following components were combined to prepare a composition: purified THC (51g), purified beta-caryophyllene (1g), purified alpha-humulene (1g) and polyethylene glycol (25 g).

Example 32:

The following components were combined to prepare a composition: purified THC (51g), purified beta-caryophyllene (1g), purified alpha-humulene (2g) and polyethylene glycol (25 g).

example 33:

the following components were combined to prepare a composition: purified THC (51g), purified β -caryophyllene (2g), purified α -humulene (2g) and polyethylene glycol (25 g).

Example 34:

The following components were combined to prepare a composition: purified THC (75g) and purified THCV (5 g).

Example 35:

The following components were combined to prepare a composition: purified THC (50g) and purified CBD (10 g).

example 36:

The following components were combined to prepare a composition: purified THC (50g) and purified CBG (5 g).

Example 37:

The following components were combined to prepare a composition: purified THC (75g) and purified CBC (15 g).

Example 38:

The following components were combined to prepare a composition: purified THC (75g) and purified CBN (10 g).

example 39:

The following components were combined to prepare a composition: purified CBD (50g) and purified α -bisabolol (50 g).

example 40:

The following components were combined to prepare a composition: purified CBC (50g) and purified α -bisabolol (50 g).

Example 41:

The following components were combined to prepare a composition: purified CBG (50g) and purified α -bisabolol (50 g).

Example 42:

The following components were combined to prepare a composition: purified CBD (50g), purified CBC (50g) and purified α -bisabolol (50 g).

Example 43:

the following components were combined to prepare a composition: purified CBD (50g), purified CBG (50g) and purified α -bisabolol (50 g).

Example 44:

The following components were combined to prepare a composition: purified CBC (50g), purified CBG (50g) and purified CBD (50 g).

example 45:

The following components were combined to prepare a composition: purified CBC (50g), purified CBG (50g) and purified CBN (50 g).

Example 46:

The clinical effect of terpene concentration was measured by comparing the difference in measured responses between (a) administration of purified cannabinoid alone and (b) administration of the same purified cannabinoid together with purified terpene. Each of the following variables was evaluated systematically: (iii) cannabinoid compounds present; terpene compounds present; and absolute and relative concentrations thereof.

In each observational study, each participant was given a formulation with a specific chemical composition according to the above guidelines. Subjective feelings were scored based on Visual Analogue Scores (VAS) in a web-based survey question 60 minutes after the subjects started to ingest the samples. Each VAS question requires the subject to click on a horizontal bar in a position that reflects their level of perception described by adjectives located at either end of the bar. Clicking on the left end of the bar returns a score of zero, and clicking on the right end returns a score of 10. The "unipolar" problem requires the subject to report a unique sensory intensity on a scale of zero (not at all) to 10 (extreme) (bodell reference). The "bipolar" question is also scored on a scale of 0 to 10. For the bipolar question, clicking in the middle of the bar (a score of 5) means that any given subject reports neutrality relative to the adjectives located at either end of the bar.

Subjective scores reported for each VAS survey were averaged and the average was compared between base oil and low and high terpene enriched samples. The small sample size in these experiments gave a implicit explanation for the sensation caused by terpene enrichment. Thus, the most significant perception caused by terpene enrichment was determined according to conservative criteria: 1) terpene enrichments move from zero to a high percentage as the average score tends towards a given VAS adjective, and 2) they tend to go from low to high when the average score changes by at least 50%.

The following table illustrates how clinical results are organized to compare trends in specific feelings when studying terpene enrichment.

These examples are non-limiting and are intended to be merely illustrative of possible embodiments of the formulations disclosed herein.

While the invention has been described with reference to various exemplary embodiments, it is to be understood that these embodiments are merely illustrative of the principles and applications of the present invention. Those skilled in the art will recognize that various modifications may be made to the exemplary embodiments without departing from the scope of the present invention.

Furthermore, it should be understood that various features and/or characteristics of the different embodiments herein may be combined with each other. It is therefore to be understood that numerous modifications may be made to the illustrative embodiments and that other arrangements may be devised without departing from the scope of the present invention.

In addition, other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a scope and spirit being indicated by the following claims.

Finally, it should be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless expressly limited to one referent and vice versa. As used herein, the terms "comprises" or "comprising" and grammatical variants thereof are intended to be non-limiting, such that recitation of one or more items is not to the exclusion of other like items that may be substituted or added to the recited item.

Claims (16)

1. A composition, comprising:

A first purified cannabinoid; and

A compound selected from the group consisting of a second purified cannabinoid; or a first purified terpene.

2. The composition of claim 1, comprising a first purified terpene.

3. the composition of claim 2, wherein the first purified terpene is selected from the group consisting of: 7, 8-dihydro- α -ionone, 7, 8-dihydro- β -ionone, acetylanisole, acetic acid, acetylcedrene, anethole, anisole, benzaldehyde, bergamotene (α -cis-bergamotene) (α -trans-bergamotene), bisabolol (β -bisabolol), α -bisabolol, borneol, bornyl acetate, butyric acid, juniperbene terpene (α -juniperbene) (λ -juniperbene), cafestol, caffeic acid, camphene, camphor, capsaicin, carene (δ -3-carene), humulene, carvacrol, dextrocarvone, levo-carvone, α -caryophyllene, β -caryophyllene, caryophyllene oxide, cedrene (α -cedrene) (β -cedrene), epoxycedrane (α -epoxycedrane), cedrol, cedrene, chlorogenic acid, cinnamaldehyde, α -amyl-cinnamaldehyde, α -hexyl-cinnamaldehyde, cinnamic acid, cinnamyl alcohol, citronellal, citronellol, cryptopine, curcumene (α -curcumene) (γ -curcumene), decanal, dehydroemethol, diallyl disulfide, dihydroactinidiolide, dimethyl disulfide, eicosane, elemene (β -elemene), artemisinine, ethyl acetate, ethyl cinnamate, ethyl maltol, eucalyptol/1, 8-cineol, eucalyptol (α -cineol) (β -cineol) (γ -cineol), eugenol, euphadienol, farnesene, farnesol (β -fenchyl), fenchyl, geraniol, geranyl acetate, germacrene B, guaiazulene-1 (10), 11-diene, guaiacol, guaiene (α -guaiene), gulene (α -gulinene), deanterazine, hexanal, hexanoic acid, humulene (α -humulene) (β -humulene), ionol (3-oxo- α -ionol) (β -ionol), ionone (α -ionone) (β -ionone), scolecanol, isoamyl acetate, isoamyl alcohol, isoamyl formate, isoborneol, isomyrcenol, isopulegol, isovaleric acid, isoprene, stigmatol, lavender alcohol, limonene, γ -linolenic acid, linalool, longifolene, α -longifolene, lycopene, menthol, methyl butyrate, 3-mercapto-2-methylpentanal, mercaptan, beta-mercaptoethanol, thioglycolic acid, allyl mercaptan, benzyl mercaptan, butyl mercaptan, ethyl mercaptan, methyl mercaptan, furfuryl mercaptan, ethanedithiol, propyl mercaptan, thienylmethyl mercaptan, methyl salicylate, methyl butenol, methyl-2-methylpentanoate, methylthiobutyrate, myrcene (beta-myrcene), gamma-menthene, nepetalactone, nerol, nerolidol, nerol acetate, nonanal, nonanoic acid, ocimene, octanal, octanoic acid, p-cymene, amyl butyrate, phellandrene, phenylacetaldehyde, phenethyl mercaptan, phenylacetic acid, phytol, pinene, beta-pinene, propanethiol, patulin, pulegone, quercetin, retinol, rutin, sabinene hydrate, cis-sabinene hydrate, trans-sabinene hydrate, safranal, alpha-apiene, alpha-sinenseal, beta-sitosterol, squalene, taxadiene, terpene diol hydrate, terpineol, 4-terpineol, alpha-terpinene, gamma-terpinene, terpinolene, thiophenol, thujone, thymol, alpha-tocopherol, coumarone undecanone, undecanal, pentanal, o-tert-butylcyclohexyl acetate, alpha-ylacene, umbelliferone, or vanillin.

4. The composition of claim 3, wherein the first purified cannabinoid is selected from the group consisting of: cannabigerolic acid (CBGA), cannabigerolic acid monomethyl ether (CBGAM), Cannabigerol (CBG), cannabigerol monomethyl ether (CBGM), cannabigerolic acid (CBGVA), Cannabigerol (CBGV), cannabichromenic acid (CBCA), cannabichromene (CBC), cannabichromenic acid (CBCVA), cannabichromene (CBCV), cannabidiolic acid (CBDA), Cannabidiol (CBD), cannabidiol monomethyl ether (CBDM), cannabidiol-C₄(CBD-C₄) Cannabidivarin diphenolic acid (CBDVA), Cannabidivarin (CBDV), cannabidiol (CBD-C)₁) Tetrahydrocannabinolic acid A (THCA-A), tetrahydrocannabinolic acid B (THCA-B), tetrahydrocannabinolic acid (THCA), Tetrahydrocannabinol (THC), tetrahydrocannabinolic acid C₄(THCA-C₄) Tetrahydrocannabinol C₄(THC-C₄) Tetrahydrocannabinolic acid (THCVA), Tetrahydrocannabivarin (THCV), tetrahydrocannabinolic acid (THCA-C)₁) Tetrahydrocannabinol (THC-C)₁)，Δ⁷-cis-Isotetrahydrocannabivarin, Δ⁸-tetrahydrocannabinolic acid (Δ)⁸-THCA), cannabinoic acid (CBNDVA), Cannabinodiol (CBNDV), Δ⁸-tetrahydrocannabinol (Δ)⁸-THC)，Δ⁹-tetrahydrocannabinol (Δ)⁹-THC), cannabichromenic acid (CBLA), Cannabichromene (CBL), Cannabigerol (CBLV), cannabigerolic acid a (CBEA-a), cannabigerolic acid B (CBEA-B), Cannabigeropine (CBE), Cannabigeropine (CBEV), cannabigerolic acid (CBEVA), cannabigerolic acid (CBEA), cannabigerolic acid (CBLV), cannabigerolic acid (CBLVA), cannabinolic acid (CBNA), Cannabigerol (CBN), cannabinolic acid (CBNVA), cannabinol monomethyl ether (CBNM), cannabinol-C₄(CBN-C₄) sub-Cannabinol (CBV), cannabinol-C₂(CBN-C₂) Cannabinol (CBN-C)₁) Large, largeCannabidiol (CBND), cannabidiolic acid (CBNDA), Cannabidivarin (CBDV), Cannabidiopyranone (CBT), 10-ethoxy-9-hydroxy-Delta^6a-tetrahydrocannabinol, 8, 9-dihydroxy-delta^6a(10a)-tetrahydrocannabinol (8, 9-Di-OH-CBT-C)₅) Dihydroxycannabidivarin (CBTV), ethoxy-dihydroxycannabidivarin (CBTVE), Dihydrocannabidivarin (DCBF), Cannabinoids (CBF), cannabichromanone (CBCN), Cannabidicarbocycloalkane (CBT), 10-oxo-Delta^6a(10a)-tetrahydrocannabinol (OTHC), Δ⁹-cis-tetrahydrocannabinol (cis-THC), canabispsol (cbr), 3,4,5, 6-tetrahydro-7-hydroxy- α -2-trimethyl-9-n-propyl-2, 6-methanol-2H-1-benzoxazocin-5-methanol (OH-iso-HHCV), trihydroxy- δ -9-tetrahydrocannabinol (trihoh-THC), kavain, epigallocatechin gallate, dodecane-2E, 4E,8Z, 10Z-tetraenoic acid isobutylamide, and dodecane-2E, 4E-dienoic acid isobutylamide.

5. the composition of claim 4, wherein the first purified cannabinoid is selected from the group consisting of: THC, D9-THC, D8-THC, THCA, THCV, D8-THCV, D9-THCV, THCVA, CBD, CBDA, CBDV, CBDVA, CBC, CBCA, CBCV, CBCVA, CBG, CBGA, CBGV, CBGVA, CBN, CBNA, CBNV, CBNVA, CBND, CBNDA, CBNDV, CBNDVA, CBE, CBEA, CBEV, CBEVA, CBL, CBLA, CBLV, or CBLVA.

6. The composition according to claim 1, wherein the first purified cannabinoid is THC, and the first purified terpene is selected from the group consisting of: limonene, nerolidol, beta-myrcene, linalool, alpha-caryophyllene, beta-caryophyllene, alpha-pinene, beta-pinene, alpha-bisabolol, delta-3-carene, borneol, p-cymene, eucalyptol, alpha-humulene, alpha-terpineol, terpinolene, pulegone, camphene, or geraniol.

7. the composition of claim 6, comprising a CBG.

8. The composition of claim 3, wherein the first purified terpene is selected from the group consisting of: limonene, nerolidol, beta-myrcene, linalool, alpha-caryophyllene, beta-caryophyllene, alpha-pinene, beta-pinene, alpha-bisabolol, delta-3-carene, borneol, p-cymene, eucalyptol, alpha-humulene, alpha-terpineol, terpinolene, pulegone, camphene, or geraniol.

9. The composition of claim 1, comprising a second purified cannabinoid.

10. The composition of claim 2, comprising a second purified cannabinoid.

11. The composition of claim 9, comprising a third purified cannabinoid.

12. the composition of claim 2, comprising a second purified terpene.

13. The composition of claim 2, wherein the first purified cannabinoid and the first purified terpene are in a non-naturally occurring ratio.

14. The composition of claim 2, wherein the first purified cannabinoid and the first purified terpene are in a non-naturally occurring concentration.

15. The composition of claim 1, wherein the composition has a purity of greater than 80%.

16. The composition of claim 1, wherein the composition has a purity of greater than 90%.